Vanilloid receptor-2

Abstract

The present invention relates to vanilloid receptor-2, a novel member of the vanilloid receptor family. The invention provides isolated nucleic acid molecules encoding human VR2 receptors. VR2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of VR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of VR2 receptors. Further provided are therapeutic methods for treating disease states including, but not limited to, chronic pain syndromes, congenital pain insensitivity, inflammation, ischemia, host defense dysfunction, immune surveillance dysfunction, arthritis, multiple sclerosis, autoimmunity, immune dysfunction, and allergy.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a novel member of the vanilloid receptor family. More specifically, the present invention relates to the discovery, identification and characterization of nucleotides that encode vanilloid receptor-2 (VR2), a receptor having homology with the rat vanilloid receptor-1 protein. The invention encompasses VR2 polynucleotides, host cell expression systems, VR2 polypeptides (including fragments, variants, derivatives and analogs thereof), VR2 fusion proteins, antibodies to VR2, agonists and antagonists of VR2, and other compounds that modulate VR2 gene expression or VR2 activity, that can be used for diagnosis, drug screening, and treatment or prevention of disorders which include, but are not limited to, chronic pain syndromes, congenital pain insensitivity, inflammation, ischemia, host defense dysfunction, immune surveillance dysfunction, arthritis, multiple sclerosis, autoimmunity, immune dysfunction, and allergy.

2. Related Art

The concentration of free Ca +2 in the cytosol of any cell is extremely low (≈10 −7 M), whereas the concentration of free Ca +2 in the extracellular fluid (≈10 −3 M) and in the endoplasmic reticulum is quite high. Thus, there is a large gradient tending to drive Ca +2 into the cytosol across both the plasma membrane and the endoplasmic reticulum membrane. When a signal transiently opens Ca +2 channels in either of these membranes, Ca +2 rushes into the cytosol, dramatically increasing the local Ca +2 concentration and triggering Ca +2 -responsive proteins in the cell. Ca +2 has been demonstrated to act as an intracellular messenger in a wide variety of cellular responses, such as, for example, transmission of an action potential in nerve cells, muscular contraction, and cell secretion, activation, survival, proliferation, migration, and differentiation.

Pain is initiated when a subgroup of sensory neurons, called nociceptors, are activated by noxious chemical, thermal or mechanical stimuli. The activated nociceptors convey information regarding the noxious stimuli to pain processing centers in the spinal cord and brain (Fields, H., Pain (McGraw-Hill, New York, 1987). Nociceptors are characterized in part, by their sensitivity to vanilloids (i.e., chemicals containing vanillyl groups), such as, for example, capsaicin, the main pungent ingredient in capsaicin peppers. In mammals, exposure of nociceptor terminals to capsaicin leads to excitation of the neuron and the consequent perception of pain and local release of inflammatory mediators. Prolonged exposure of nociceptor terminals to capsaicin leads to the desensitization of these neurons to capsaicin and other noxious stimuli (Szolcsanyi, Y., in Capsaicin and the Study of Pain (ed. Wood J.) 255-272 (Academic, London, 1993). This phenomenon of desensitization has led to the use of capsaicin as an analgesic agent in the treatment of painful disorders ranging from viral and diabetic neuropathies to rheumatoid arthritis (Campbell, E., in Capsaicin and the Study of Pain (ed. Wood J.) 255-272 (Academic, London, 1993; Szallasi et al., Pain 68:195-208 (1996)).

Recently, a cDNA encoding vanilloid receptor subtype-1 (VR1), has been isolated from a rodent dorsal root ganglion plasmid cDNA library (Caterina et al., Nature 389:816-824 (1997). This clone encodes a polytopic integral membrane protein containing six transmembrane domains, four extracellular domains, four intracellular domains, and an additional short hydrophobic region between transmembrane domains five and six that may contribute to an ion permeation path (Hardie et al., Trends Neurosci . 16:371-376 (1993)). The product of this clone is a calcium permeable, non-selective cation channel that is structurally related to members of the TRP family of ion channels (see, e.g., Montell et al., Neuron 2:1313-1333 (1989); and Hardie et al., Trends Neurosci . 16:371-376 (1993)).

Capsaicin binding to VR1 has been demonstrated to trigger an increase in intracellular free calcium. Additionally, transfection of VR1 into non-neuronal cells has been shown to induce cytotoxicity upon continuous exposure to capsaicin. These observations are consistent with necrotic cell death resulting from excessive ion influx.

VR1 is activated (i.e., the VR1 cation-selective channel is opened), by capsaicin, capsaicin agonists, and other vanilloid compounds (e.g., resiniferatoxin), and antagonized by capsaicin antagonists (e.g., capsazepine and ruthenium red). Further, hydrogen ions potentiate the response of VR1 to low concentrations of capsaicin: thus, VR1 may be involved in the detection of noxious stimuli that accompany such conditions as inflammation and ischemia (Caterina et al, Nature 389:819-824 (1997).

Additionally, VR1 is activated when ambient temperatures are elevated to elicit pain in humans or pain associated behaviors in animals, indicating that, in addition to its role in transducing noxious chemical stimuli, VR1 functions as a transducer of painful thermal stimuli in vivo (Caterina et al., Nature 389:816-824 (1997).

The involvement of a vanilloid receptor family member in transducing thermal and chemical stimuli suggests that members of this family of cation channels are involved in diverse human disease states ranging from congenital pain insensitivity, to chronic pain syndromes and more generally that members of this family mediate cellular responses such as cell secretion, activation, survival, proliferation, migration and differentiation; that vanilloid receptor family members provide an important model system for the in vitro study of hyperalgesia; and that vanilloid receptors provide defined targets for the development of new analgesic agents.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acid molecules comprising polynucleotides encoding a VR2 receptor having the amino acid sequence shown in FIGS. 1A-1D (SEQ ID NO:2) or the amino acid sequence encoded by the cDNA clone encoding the VR2 receptor deposited in a vector as ATCC Deposit Number 263082 on Jul. 30, 1998. The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells and for using them or other genetically modified host cells to produce VR2 polypeptides (including fragments, variants, derivatives, and analogs thereof) by recombinant techniques.

The invention further provides isolated VR2 polypeptides having amino acid sequences encoded by the polynucleotides described herein.

The present invention also provides a screening method for identifying compounds capable of eliciting a cellular response induced by VR2, which involves contacting cells which express VR2 with the candidate compound, assaying a cellular response (e.g., ion flux, such as, Ca +2 flux), and comparing the cellular response to a standard cellular response, the standard being assayed in absence of the candidate compound; whereby, an increased cellular response over the standard indicates that the compound is an agonist.

The present invention also provides a screening method for identifying compounds capable of enhancing or inhibiting a cellular response induced by VR2 receptors, which involves contacting cells which express VR2 receptors with the candidate compound in the presence of a VR2 agonist (e.g., a vanilloid compound, such as capsaicin) or other stimulus (e.g., thermal stimuli), assaying a cellular response (e.g., ion flux, such as, Ca +2 flux), and comparing the cellular response to a standard cellular response, the standard being assayed when contact is made between the agonist and VR2 or when VR2 is exposed to the stimulus, in absence of the candidate compound; whereby, an increased cellular response over the standard indicates that the compound is an agonist and a decreased cellular response over the standard indicates that the compound is an agonist

In another embodiment, a screening assay for agonists and antagonists is provided which involves determining the effect a candidate compound has on the binding of cellular ligands (e.g., vanilloid compounds, such as, capsaicin) to VR2. In particular, the method involves contacting VR2 with a ligand or other stimulus (e.g., thermal stimuli) and a candidate compound and determining whether ligand binding to the VR2 receptors is increased or decreased due to the presence of the candidate compound.

The invention further provides a diagnostic method useful during diagnosis or prognosis of disease states resulting from aberrant pain sensitivity, or aberrant cell secretion, activation, survival, migration, differentiation and/or proliferation, due to alterations in VR2 coding sequences and/or receptor expression.

An additional embodiment of the invention is related to a method for treating an individual in need of an increased level of VR2 activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of VR2 polypeptides or polynucleotides of the invention or a VR2 agonist.

A still further embodiment of the invention is related to a method for treating an individual in need of a decreased level of a VR2 receptor activity in the body comprising, administering to such an individual a composition comprising a therapeutically effective amount of VR2 polypeptides or polynucleotides of the invention a VR2 antagonist.

The invention additionally provides soluble forms of the polypeptides of the present invention. Soluble peptides are defined by amino acid sequences wherein the sequence comprises the polypeptide sequence lacking a transmembrane domain (e.g., VR2 polypeptide fragments corresponding to intracellular and/or extracellular domains). Such soluble forms of the VR2 receptor are useful as antagonists of the membrane bound forms of the receptor.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-D show the nucleotide sequence (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of the VR2 receptor. The deduced complete amino acid sequence includes 889 amino acid residues and has a deduced molecular weight of about 99,765 Da. The predicted domains of the VR2 polypeptide are: N-terminal intracellular domain 1 (amino acid residues M-1 to about N-520 of SEQ ID NO:2), ankyrin repeat domain 1 (within N-terminal intracellular domain; amino acid residues from about R-288 to about C-320 of SEQ ID NO:2), ankyrin repeat domain 2 (within N-terminal intracellular domain; amino acid residues from about F-334 to about A-366 of SEQ ID NO:2), ankyrin repeat domain 3 (within N-terminal intracellular domain; amino acid residues from about Q-419 to about H-449 of SEQ ID NO:2), transmembrane domain 1 (amino acid residues from about F-517 to about H-537 of SEQ ID NO:2); extracellular domain 1 (amino acid residues from about Q-538 to about I-562 of SEQ ID NO:2), transmembrane domain 2 (amino acid residues from about L-563 to about Y-578 of SEQ ID NO:2); intracellular domain 2 (amino acid residues from about F-579 to about D-592 of SEQ ID NO:2), transmembrane domain 3 (amino acid residues from about S-593 to about F-614 of SEQ ID NO:2); extracellular domain 2 (amino acid residues from about L-615 to about V-625 of SEQ ID NO:2), transmembrane domain 4 (amino acid residues from about S-626 to about I-652 of SEQ ID NO:2); intracellular domain 3 (amino acid residues from about Q-653 to about D-659 of SEQ ID NO:2), transmembrane domain 5 (amino acid residues from about L-660 to about V-679 of SEQ ID NO:2); extracellular domain 3 (amino acid residues from about S-680 to about N-711 of SEQ ID NO:2), pore loop (amino acid residues from about G-712 to about G-733 of SEQ ID NO:2), extracellular domain 4 (amino acid residues from about E-734 to about H-742 of SEQ ID NO:2), transmembrane domain 6 (amino acid residues from about F-743 to about S-771 of SEQ ID NO:2); and C-terminal intracellular domain 4 (amino acids from about E-772 to about N-889 of SEQ ID NO:2). The transmembrane domains are underscored.

FIGS. 2A-2D show the regions of similarity between the amino acid sequences of the VR2 receptor protein of FIGS. 1A-1D (labeled VR2.prot; SEQ ID NO:2) and rat vanilloid receptor subtype 1 protein (SEQ ID NO:3) which is labeled “VR1prot” (GenBank Accession Number 2570933 (AF029310)). Identical amino acid residues between VR1 and VR2 are shaded.

FIG. 3 shows a structural analysis of the VR2 receptor amino acid sequence of FIGS. 1A-1D (SEQ ID NO:2), generated using the default parameters of the recited computer programs. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown. In the “Antigenic Index-Jameson-Wolf” graph, amino acid residues: C-9 to L-24; from A-28 to C-37, from W-46 to H-65, from T-83 to P-134; from E-139 to P-178; from R-181 to N-207; from V-209 to G-219; from E-222 to L-246; from L-251 to N-258; from Q-266 to P-274; from T-283 to S-291; from 1-297 to Q-303; from V-309 to A-313; from R-318 to T-330; from C-344 to D-349; from L-355 to A-362; from Q-365 to N-372; from S-382 to E-387; from Q-411 to E-434; from R-442 to G-446; from L-450 to T-455; from A-470 to V-480; from C-488 to R-495; from P-539 to N-554; from E-684 to Q-714; from R-804 to A-809; from G-816 to E-833; and from E-840 to Y-880 as depicted in FIGS. 1A-1D (SEQ ID NO:2) correspond to the shown highly antigenic regions of the VR2 receptor protein.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides isolated nucleic acid molecules comprising polynucleotides encoding a VR2 polypeptide ( FIGS. 1A-1D (SEQ ID NO:2)), the amino acid sequence of which was determined by sequencing a cloned cDNA (Clone HMAJ106). The VR2 protein shown in FIGS. 1A-1D shares sequence homology with rat vanilloid receptor subtype 1 ( FIGS. 2A-2D (SEQ ID NO:3)). The nucleotide sequence shown in FIGS. 1A-1D (SEQ ID NO:1) was obtained by sequencing a cDNA clone (Clone HMAJI06). On Jul. 30, 1998, the plasmid corresponding to this clone was deposited with the American Type Culture Collection, 10801 University Blvd, Manassas, Va., 20110-2209, and was assigned accession number 263052. The deposited cDNA is contained in the UniZAP XR plasmid (Stratagene, La Jolla, Calif.).

As used herein, “VR2 protein”, “VR2 receptor”, “receptor protein”, “VR2”, and “VR2 polypeptide” refer to all polypeptides resulting from the alternate splicing of the genomic DNA sequences encoding proteins having regions of amino acid sequence identity and receptor activity which correspond to the protein shown in FIGS. 1A-1D (SEQ ID NO:2). The VR2 protein shown in FIGS. 1A-1D is an example of such a receptor protein.

Nucleic Acid Molecule

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

Using the information provided herein, such as the nucleotide sequence in FIGS. 1A-1D (SEQ ID NO: 1), nucleic acid molecules of the present invention encoding VR2 polypeptides may be obtained using standard cloning and screening procedures, such as those used for cloning cDNAs using MRNA as starting material. Northern analysis has revealed expression of the VR2 transcript in a variety of tissues, with highest levels in the spleen, lymph node, peripheral blood leukocytes, and lung; next highest levels of expression were observed in the thymus, heart, placenta, brain, bone marrow and fetal liver; and lower expression in other tissues. Thus, any of these tissues or cell types provide a source of VR2 mRNA. Additionally, any tissue or cell source may be utilized to routinely clone VR2 genomic DNA using techniques known in the art. Illustrative of the invention, the nucleic acid molecule described in FIGS. 1A-1D (SEQ ID NO:1) was discovered in a cDNA library derived from GM-CSF treated macrophages.

The determined nucleotide sequence of the VR2 cDNA of FIGS. 1A-1D (SEQ ID NO: 1) contains an open reading frame encoding a polytopic polypeptide of about 889 amino acid residues, with 4 intracellular domains, 6 transmembrane domains, 4 extracellular domains, and a pore loop, and having a deduced molecular weight of about 99,765 Da. The VR2 protein shown in FIGS. 1A-1D (SEQ ID NO:2) is predicted to be about 51% identical and about 60% similar to the rat VR1 protein depicted in SEQ ID NO:3 (see FIGS. 2A-2D ) using the computer program “Bestfit” (see below). In addition to having homology, VR1 and VR2 share the same predicted topological organization. For example, like VR1, VR2 contains 4 intracellular and 4 extracellular domains, 6 transmembrane domains with a pore loop between transmembrane regions 5 and 6, and three ankyrin repeat motifs in the amino terminal hydrophilic domain. As discussed above, VR1 has been shown to be a cation selective heat and chemical activated ion channel in the pain pathway.

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand or complementary strand.

By “isolated” nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the DNA molecules of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. However, a nucleic acid contained in a clone that is a member of a library (e.g., a genomic or cDNA library) that has not been isolated from other members of the library (e.g., in the form of a homogeneous solution containing the clone and other members of the library) or which is contained on a chromosome preparation (e.g., a chromosome spread), is not “isolated” for the purposes of this invention. Isolated nucleic acid molecules according to the present invention may be produced naturally, recombinantly, or synthetically.

In one embodiment, nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) shown in FIGS. 1A-1D (SEQ ID NO:1); and DNA molecules which comprise a sequence substantially different from those described above, but which, due to the degeneracy of the genetic code, still encode the VR2 receptor polypeptide shown in FIGS. 1A-1D (SEQ ID NO:2). Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate variants.

In another embodiment, the invention provides isolated nucleic acid molecules encoding the VR2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in the plasmid deposited as ATCC Deposit No. 203082 on Jul. 30, 1998. In a further embodiment, these nucleic acid molecules encode the full-length polypeptide lacking the N-terminal methionine (amino acid residues 2 to 889 of SEQ ID NO:2). The invention further provides isolated nucleic acid molecules having the nucleotide sequences shown in FIGS. 1A-1D (SEQ ID NO:1), the nucleotide sequence of the cDNA contained in the above-described deposited clone (clone HMAJI06); or nucleic acid molecules having a sequence complementary to one of the above sequences. Such isolated molecules, particularly DNA molecules, have uses that include, but are not limited to, probes for gene mapping by in situ hybridization with chromosomes, and for detecting expression of the VR2 genes of the present invention in human tissue, for instance, by Northern blot analysis.

The present invention is further directed to fragments of the isolated nucleic acid molecules (i.e. polynucleotides) described herein. By a fragment of an isolated nucleic acid molecule having, for example, the nucleotide sequence of the deposited cDNA (clone HMAJI06), a nucleotide sequence encoding the polypeptide sequence encoded by the deposited cDNA, a nucleotide sequence encoding the polypeptide sequence depicted in FIGS. 1A-1D (SEQ ID NO:2), the nucleotide sequence shown in FIGS. 1A-1D (SEQ ID NO:1), or the complementary strand thereto, is intended fragments at least 15 nt, and more preferably at least about 20 nt, still more preferably at least 30 nt, and even more preferably, at least about 40, 50, 100, 150, 200, 250, 300, 325, 350, 375, 400, 450, 500, 550, or 600 nt in length. These fragments have numerous uses which include, but are not limited to, diagnostic probes and primers as discussed herein. Of course, larger fragments, such as those of 501-1500 nt in length are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequences of the deposited cDNA (clone HMAJI06) or as shown in FIGS. 1A-1D (SEQ ID NO:1). By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from, for example, the nucleotide sequence of the deposited cDNA, or the nucleotide sequence as shown in FIGS. 1A-1D (SEQ ID NO:1).

Representative examples of VR2 polynucleotide fragments of the invention include, for example, fragments that comprise, or alternatively, consist of, a sequence from about nucleotide 1 to 50, 51 to 100, 101 to 150, 151 to 200, 201 to 250, 251 to 300, 301 to 350, 351 to 400, 401 to 450, 451 to 500, 501 to 550, 551 to 600, 600 to 650, 651 to 700, 701 to 750, 751 to 800, 800 to 850, 851 to 900, 901 to 950, 951 to 1000, 1001 to 1050, 1051 to 1100, 1101 to 1150, 1151 to 1200, 1201 to 1250, 1251 to 1300, 1301 to 1350, 1351 to 1400, 1401 to 1450, 1451 to 1500, 1501 to 1550, 1551 to 1600, 1601 to 1650, 1651 to 1700, 1701 to 1750, 1751 to 1800, 1801 to 1850, 1851 to 1900, 1901 to 1950, 1951 to 2000, 2001 to 2050, 2051 to 2100, 2101 to 2150, 2151 to 2200, 2201 to 2250, 2251 to 2300, 2301 to 2350, 2351 to 2400, 2401 to 2450, 2451 to 2500, 2501 to 2550, 2551 to 2600, 2601 to 2650, 2651 to 2700, and/or 2701 to 2750, of SEQ ID NO:1, or the complementary strand thereto, or the cDNA contained in the deposited clone. In this context “about” includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.

In specific embodiments, the polynucleotide fragments of the invention comprise, or alternatively, consist of, a sequence from nucleotide 961 to 1000, 1730 to 1770, 1770 to 1800, and/or 1800 to 1840, of SEQ ID NO:1, or the complementary strand thereto.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a VR2 functional activity. By a polypeptide demonstrating “functional activity” is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length VR2 polypeptide. Such functional activities include, but are not limited to, biological activity (e.g., ion flux (e.g, Ca +2 flux)), antigenicity [ability to bind (or compete with a VR2 polypeptide for binding) to an anti-VR2 antibody], immunogenicity (ability to generate antibody which binds to a VR2 polypeptide), and ability to bind to a receptor or ligand for a VR2 polypeptide (e.g., a vanilloid compound (e.g., capsaicin, resiniferatoxin, and capsazepine)).

Preferred nucleic acid fragments of the invention include nucleic acid molecules encoding one or more VR2 receptor domains. In particular embodiments, such nucleic acid fragments comprise, or alternatively consist of, nucleic acid molecules encoding: a polypeptide selected from the group consisting of: (a) N-terminal intracellular domain 1 (amino acid residues M-1 to about N-520 of SEQ ID NO:2); (b) ankyrin repeat domain 1 (within N-terminal intracellular domain; amino acid residues from about R-288 to about C-320 of SEQ ID NO:2); (c) ankyrin repeat domain 2 (within N-terminal intracellular domain; amino acid residues from about F-334 to about A-366 of SEQ ID NO:2); (d) ankyrin repeat domain 3 (within N-terminal intracellular domain; (e) amino acid residues from about Q-419 to about H-449 of SEQ ID NO:2); (f) transmembrane domain 1 (amino acid residues from about F-517 to about H-537 of SEQ ID NO:2); (g) extracellular domain 1 (amino acid residues from about Q-538 to I-562 of SEQ ID NO:2); (h) transmembrane domain 2 (about L-563 to about Y-578 of SEQ ID NO:2); (i) intracellular domain 2 (amino acid residues from about F-579 to about D-592 of SEQ ID NO:2); (j) transmembrane domain 3 (amino acid residues from about S-593 to about F-614 of SEQ ID NO:2); (k) extracellular domain 2 (amino acid residues from about L-615 to about V-625 of SEQ ID NO:2); (l) transmembrane domain 4 (amino acid residues from about S-626 to about 1-652 of SEQ ID NO:2); (m) intracellular domain 3 (amino acid residues from about Q-653 to about D-659 of SEQ ID NO:2); (n) transmembrane domain 5 (amino acid residues from about L-660 to about V-679 of SEQ ID NO:2); (o) extracellular domain 3 (amino acid residues from about S-680 to about N-711 of SEQ ID NO:2); (p) pore loop (amino acid residues from about G-712 to about G-733 of SEQ ID NO:2); (q) extracellular domain 4 (amino acid residues from about E-734 to about H-742 of SEQ ID NO:2); (r) transmembrane domain 6 (amino acid residues from about F-743 to about S-771 of SEQ ID NO:2); (s) C-terminal intracellular domain 4 (amino acid residues from about E-772 to about N-889 of SEQ ID NO:2); (t) any combination of polypeptides (a)-(s); and (u) the complementary strand of the sense strand encoding any of polypeptides (a)-(s).

The amino acid residues constituting the extracellular, transmembrane and intracellular domains have been predicted by computer analysis. Thus, as one of ordinary skill would appreciate, the amino acid residues constituting these domains may vary slightly (e.g., by about 1 to about 15 amino acid residues) depending on the criteria used to define each domain.

Preferred nucleic acid fragments of the invention also include nucleic acid molecules encoding epitope-bearing portions of the VR2 receptor. In particular, such nucleic acid fragments of the present invention include nucleic acid molecules encoding: a polypeptide comprising, or alternatively consisting of, amino acid residues: from C-9 to L-24; from A-28 to C-37; from W-46 to H-65; from T-83 to P-134; from E-139 to P-178; from R-181 to N-207; from V-209 to G-219; from E-222 to L-246; from L-251 to N-258; from Q-266 to P-274; from T-283 to S-291; from I-297 to Q-303; from V-309 to A-313; from R-318 to T-330; from C-344 to D-349; from L-355 to A-362; from Q-365 to N-372; from S-382 to E-387; from Q-411 to E-434; from R-442 to G-446; from L-450 to T-455; from A-470 to V-480; from C-488 to R-495; from P-539 to N-554; from E-684 to Q-714; from R-804 to A-809; from G-816 to E-833; and/or from E-840 to Y-880 of SEQ ID NO:2. The inventors have determined that the above polypeptides are antigenic regions of the VR2 polypeptide. Methods for determining other such epitope-bearing portions of VR2 polypeptides are described in detail below.

In addition, the present inventors have identified the following cDNA clones related to portions of the sequence shown in SEQ ID NO: 1: HMSBA20R (SEQ ID NO:9); HAFAU18R (SEQ ID NO: 10); HJPAK91R (SEQ ID NO:11); HCETB29R (SEQ ID NO: 12); HBGBT42R (SEQ ID NO:13); HTOFC66R (SEQ ID NO: 14); HTPCA74R (SEQ ID NO: 15); HWABR13R (SEQ ID NO: 16) and HDPMS61R (SEQ ID NO:17). ID NO:60); GenBank Accession No. AA121981 (SEQ ID NO:61); GenBank Accession No. AA121980 (SEQ ID NO:62); GenBank Accession No. T12252 (SEQ ID NO:63); GenBank Accession No. AA015295 (SEQ ID NO:64); GenBank Accession No. AA274980 (SEQ ID NO:65); GenBank Accession No. AA139413 (SEQ ID NO:66); and GenBank Accession No. AA236416 (SEQ ID NO:67).

In another embodiment, the invention provides isolated nucleic acid molecules comprising polynucleotides which hybridize, preferably under stringent hybridization conditions, to a portion of one or more of the nucleic acids (i.e., polynucleotides) described herein, such as, for instance, the cDNA clone contained in ATCC Deposit 203082, the polynucleotide sequence depicted in FIGS. 1A-1D (SEQ ID NO: 1) or the complementary strand thereto, and/or any of the polynucleotide fragments as described herein. By “stringent hybridization conditions” is intended overnight incubation at 42° C. in a solution comprising: 50% formamide, 5×SSC (750 mM Nacl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1×SSC at about 65° C. By a polynucleotide which hybridizes to a “portion” of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least 15 nucleotides (nt), and more preferably at least 20 nt, still more preferably at least 30 nt, and even more preferably 30-70, or 80-150 nt, or the entire length of the reference polynucleotide. By a portion of a polynucleotide of “at least 20 nt in length,” for example, is intended 20 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., the deposited cDNA or the complementary strand of the nucleotide sequence shown in FIGS. 1A-1D (SEQ ID NO: 1)). Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3′ terminal poly(A) tail of a cDNA sequence), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a

The following public ESTs, which relate to portions of SEQ ID NO:1, have also been identified: GenBank Accession No. N29128 (SEQ ID NO:18); GenBank Accession No. AA741232 (SEQ ID NO: 19); GenBank Accession No. W44731 (SEQ ID NO:20); GenBank Accession No. N28029 (SEQ ID NO:21), GenBank Accession No. N35179 (SEQ ID NO:22); GenBank Accession No. AA768829 (SEQ ID NO:23); GenBank Accession No. H20025 (SEQ ID NO:24); GenBank Accession No. W38665 (SEQ ID NO:25), GenBank Accession No. AA281348 (SEQ ID NO:26), GenBank Accession No. W92895 (SEQ ID NO:27); GenBank Accession No. AA461295 (SEQ ID NO:28); GenBank Accession No. AA815110 (SEQ ID NO:29); GenBank Accession No. H20101 (SEQ ID NO:30); GenBank Accession No. N23395 (SEQ ID NO:31); GenBank Accession No. AA236417 (SEQ ID NO:32); GenBank Accession No. AA459710 (SEQ ID NO:33); GenBank Accession No. H51393 (SEQ ID NO:34); GenBank Accession No. H49128 (SEQ ID NO:35); GenBank Accession No. N26729 (SEQ ID NO:36); GenBank Accession No. N21167 (SEQ ID NO:37); GenBank Accession No. W92818 (SEQ ID NO:38); GenBank Accession No. H50404 (SEQ ID NO:39); GenBank Accession No. AA304033 (SEQ ID NO:40); GenBank Accession No. N34617 (SEQ ID NO:41); GenBank Accession No. H50364 (SEQ ID NO:42); GenBank Accession No. AA281349 (SEQ ID NO:43); GenBank Accession No. N24224 (SEQ ID NO:44); GenBank Accession No. AA357145 (SEQ ID NO:45); GenBank Accession No. W82502 (SEQ ID NO:46); GenBank Accession No. H99578 (SEQ ID NO:47); GenBank Accession no. N21284 (SEQ ID NO:48); GenBank Accession No. H51392 (SEQ ID NO:49); GenBank Accession No. H21490 (SEQ ID NO:50); GenBank Accession No. H49060 (SEQ ID NO:51); GenBank Accession No. AA476107 (SEQ ID NO:52); GenBank Accession No. H27879 (SEQ ID NO:53); GenBank Accession No. H40615 (SEQ ID NO:54); GenBank Accession No. AA814328 (SEQ ID NO:55); GenBank Accession No. T12251 (SEQ ID NO:56); GenBank Accession No. T71250 (SEQ ID NO:57); GenBank Accession No. H99192 (SEQ ID NO:58); GenBank Accession No. T90814 (SEQ ID NO:59); GenBank Accession No. N24475 (SEQ poly (A) stretch or the complement thereof (i.e., practically any double-stranded cDNA clone generated using oligo dT as a primer). These polynucleotides have uses which include, but are not limited to, diagnostic probes and primers as discussed above and in more detail below.

In specific embodiments, the nucleic acid molecules of the invention hybridize to the complementary strand of nucleotides 961 to 1000, 1730 to 1770, 1770 to 1800, and/or 1800 to 1840 of SEQ ID NO:1.

As indicated, nucleic acid molecules of the present invention which encode VR2 polypeptides may include, but are not limited to, those encoding the amino acid sequences of the full-length polypeptide (SEQ ID NO:2), by itself, the coding sequence for full-length polypeptide together with additional, non-coding sequences, including for example, but not limited to, introns and non-coding, 5′ and 3′ sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals, for example—ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities. Thus, the sequence encoding the polypeptides may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The “HA” tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson et al, Cell 37:767 (1984). As discussed below, other such fusion proteins include the VR2 receptors fused to IgG-Fc at the N- or C-terminus.

The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode fragments (i.e., portions), analogs or derivatives of the VR2 receptor. Variants may occur naturally, such as a natural allelic variant. By an “allelic variant” is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

Such variants include those produced by nucleotide substitutions, deletions or additions, which may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the VR2 receptor or fragments thereof. Also especially preferred in this regard are conservative substitutions.

Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical to: (a) a nucleotide sequence encoding the VR2 polypeptide having the complete (i.e., full-length) amino acid sequence shown in FIGS. 1A-1D (SEQ ID NO:2); (b) a nucleotide encoding the complete amino sequence shown in FIGS. 1A-1D but lacking the N-terminal methionine (amino acid residues 2 to 889 in (SEQ ID NO:2)); (c) a nucleotide sequence encoding the VR2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 203082; (d) a nucleotide sequence encoding the VR2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Number 203082 but lacking the N-terminal methionine; (e) a nucleotide sequence encoding the N-terminal intracellular domain 1 of VR2 (amino acid residues M-1 to about N-520 of FIGS. 1A-1D (SEQ ID NO:2)); (f) a nucleotide sequence encoding ankyrin repeat domain 1 (within N-terminal intracellular domain; amino acid residues from about R-288 to about C-320 of FIGS. 1A-1D (SEQ ID NO:2)); (g) a nucleotide sequence encoding ankyrin repeat domain 2 (within N-terminal intracellular domain; amino acid residues from about F-334 to about A-366 of FIGS. 1A-1D (SEQ ID NO:2)); (h) a nucleotide sequence encoding ankyrin repeat domain 3 (within N-terminal intracellular domain; amino acid residues from about Q-419 to about H-449 of FIGS. 1A-1D (SEQ ID NO:2)); (i) a nucleotide sequence encoding transmembrane domain 1 (amino acid residues from about F-517 to about H-537 of FIGS. 1A-1D (SEQ ID NO:2)); (j) a nucleotide sequence encoding extracellular domain 1 (amino acid residues from about Q-538 to I-562 of FIGS. 1A-1D (SEQ ID NO:2)); (k) a nucleotide sequence encoding transmembrane domain 2 (amino acid residues from about L-563 to about Y-578 of FIGS. 1A-1D (SEQ ID NO:2)); (l) a nucleotide sequence encoding intracellular domain 2 (amino acid residues from about F-579 to about D-592 of FIGS. 1A-1D (SEQ ID NO:2)); (m) a nucleotide sequence encoding transmembrane domain 3 (amino acid residues from about S-593 to about F-614 of FIGS. 1A-D (SEQ ID NO:2)); (n) a nucleotide sequence encoding extracellular domain 2 (amino acid residues from about L-615 to about V-625 of FIGS. 1A-D (SEQ ID NO:2)); (o) a nucleotide sequence encoding transmembrane domain 4 (amino acid residues from about S-626 to about I-652 of FIGS. 1A-1D (SEQ ID NO:2)); (p) a nucleotide sequence encoding intracellular domain 3 (amino acid residues from about Q-653 to about D-659 of FIGS. 1A-1D (SEQ ID NO:2)); (q) a nucleotide sequence encoding transmembrane domain 5 (amino acid residues from about L-660 to about V-679 of FIGS. 1A-1D (SEQ ID NO:2)); (r) a nucleotide sequence encoding extracellular domain 3 (amino acid residues from about S-680 to about N-711 of FIGS. 1A-1D (SEQ ID NO:2)); (s) a nucleotide sequence encoding pore loop (amino acid residues from about G-712 to about G-733 of FIGS. 1A-1D ; SEQ ID NO:2)); (t) a nucleotide sequence encoding extracellular domain 4 (amino acid residues from about E-734 to about H-742 of FIGS. 1A-1D (SEQ ID NO:2)); (u) a nucleotide sequence encoding transmembrane domain 6 (amino acid residues from about F-743 to about S-771 of FIGS. 1A-1D (SEQ ID NO:2)); (v) and a nucleotide sequence encoding the C-terminal intracellular domain 4 (amino acid residues from about E-772 to about N-889 of FIGS. 1A-1D (SEQ ID NO:2)); (w) any fragment described herein; (x) the polypeptide sequence of FIGS. 1A-1D (SEQ ID NO:2) minus a portion, or all of, one or more of the extracellular domains, transmembrane domains, intracellular domains, ankyrin repeat domains, and pore loop of the VR2 receptor shown in FIGS. 1A-1D (SEQ ID NO:2); and (y) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), or (x).

By a polynucleotide having a nucleotide sequence at least, for example, 95% “identical” to a reference nucleotide sequence encoding a VR2 polypeptide is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the VR2 receptor. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The reference (query) sequence may be the entire VR2 encoding nucleotide sequence shown in FIGS. 1A-1D (SEQ ID NO:1) or any VR2 polynucleotide fragment as described herein.

As a practical matter, whether any particular nucleic acid molecule is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the encoding nucleotide sequence shown in FIGS. 1A-1D (SEQ ID NO:1), or to the nucleotide sequence of the deposited cDNA clone, can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711. Bestfit uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

In a specific embodiment, the identity between a reference (query) sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, is determined using the FASTDB computer program based on the algorithm of Brutlag et al., Comp. App. Biosci . 6:237-245 (1990)). Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter. According to this embodiment, if the subject sequence is shorter than the query sequence because of 5′ or 3′ deletions, not because of internal deletions, a manual correction is made to the results to take into consideration the fact that the FASTDB program does not account for 5′ and 3′ truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5′ or 3′ ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5′ and 3′ of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. A determination of whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of this embodiment. Only bases outside the 5′ and 3′ bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score. For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5′ end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5′ end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5′ and 3′ ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5′ or 3′ of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5′ and 3′ of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of this embodiment.

The present application is directed to nucleic acid molecules at least 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequences (i.e., polynucleotides) disclosed herein, irrespective of whether they encode a polypeptide having VR2 functional activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having VR2 functional activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having VR2 functional activity include, but are not limited to, inter alia, (1) isolating a VR2 receptor gene or allelic or splice variants thereof in a cDNA library; (2) in situ hybridization (e.g., “FISH”) to metaphase chromosomal spreads to provide precise chromosomal location of a VR2 receptor gene, as described in Verma et al., Human Chromosomes: A Manual of Basic Techniques , Pergamon Press, New York (1988); and (3) Northern Blot analysis for detecting VR2 mRNA expression in specific tissues.

Preferred, however, are nucleic acid molecules having sequences at least 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequences disclosed herein, which do, in fact, encode a polypeptide having VR2 functional activity. By “a polypeptide having VR2 receptor functional activity” is intended polypeptides exhibiting activity similar, but not necessarily identical, to an activity of the VR2 receptors of the present invention (either the full-length polypeptide, or the splice variants), as measured, for example, in a particular immunoassay or biological assay. For example, VR2 activity can be measured by determining the ability of a VR2 polypeptide to bind a VR2 ligand (e.g., vanilloid compounds, such as, capsaicin) and/or to serve as a thermal and/or chemical activated cation (e.g., calcium) channel. VR2 receptor activity may also be measured by determining the ability of a polypeptide, such as cognate ligand which is free or expressed on a cell surface, to induce cation flux in cells expressing the polypeptide.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of the deposited cDNA, the nucleic acid sequence shown in FIGS. 1A-1D (SEQ ID NO:1), or fragments thereof, will encode polypeptides “having VR2 functional activity.” In fact, since degenerate variants of any of these nucleotide sequences all encode the same polypeptide, in many instances, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having VR2 functional activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid).

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247:1306-13 10 (1990), wherein the authors indicate that proteins are surprisingly tolerant of amino acid substitutions.

Vectors and Host Cells

The present invention also relates to vectors which include the isolated DNA molecules (i.e., polynucleotides) of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of VR2 polypeptides or fragments thereof using these host cells or host cells that have otherwise been genetically engineered using techniques known in the art to express a polypeptide of the invention.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

In one embodiment, the polynucleotide of the invention is operatively associated with an appropriate heterologous regulatory element (e.g., promoter or enhancer), such as the phage lambda PL promoter, the E. coli lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters or enhancers will be known to the skilled artisan.

In embodiments in which vectors contain expression constructs, these constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the vector expression constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate heterologous hosts include, but are not limited to, bacterial cells, such as E. coli , Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pHE4, pA2; and PO4, pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pVR240, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Selection of appropriate vectors and promoters for expression in a host cell is a well known procedure and the requisite techniques for expression vector construction, introduction of the vector into the host and expression in the host are routine skills in the art.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., VR2 coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with VR2 polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous VR2 polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous VR2 polynucleotide sequences via homologous recombination (see, e.g., U.S. Pat. No. 5,641,670, issued Jun. 24, 1997; International Publication No. WO 96/29411, published Sep. 26, 1996; International Publication No. WO 94/12650, published Aug. 4, 1994; Koller et al., Proc. Natl. Acad Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

The host cell can be a higher eukaryotic cell, such as a mammalian cell (e.g., a human derived cell), or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. The host strain may be chosen which modulates the expression of the inserted gene sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus expression of the genetically Engineered polypeptide may be controlled. Furthermore, different host cells have characteristics and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation, cleavage) of proteins. Appropriate cell lines can be chosen to ensure the desired modifications and processing of the foreign protein expressed.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986).

The polypeptide may be expressed in a modified form, such as a fusion protein (comprising the polypeptide joined via a peptide bond to a heterologous protein sequence (of a different protein)), and may include not only secretion signals, but also additional heterologous functional regions. Such a fusion protein can be made by ligating polynucleotides of the invention and the desired nucleic acid sequence encoding the desired amino acid sequence to each other, by methods known in the art, in the proper reading frame, and expressing the fusion protein product by methods known in the art. Alternatively, such a fusion protein can be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Additionally, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery, for example, human proteins, such as, human hIL-5 receptor have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See, Bennett et al., J. Mol. Recog . 8:52-58 (1995) and Johanson et al., J. Biol. Chem . 270(16):9459-9471 (1995).

VR2 polypeptides (including fragments, variants, derivatives, and analogs thereof) can be recovered and purified from recombinant cell cultures by standard methods which include, but are not limited to, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated. or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, or alternatively, may be missing the N-terminal methonine, in some cases as a result of host-mediated processes.

VR2 Polypeptides and Fragments

The invention further provides isolated VR2 polypeptides having the amino acid sequence encoded by the deposited cDNA (i.e., clone HMAJI06), the amino acid sequence depicted in FIGS. 1A-1D (SEQ ID NO:2), or a polypeptide comprising a fragment (i.e., portion) of the above polypeptides.

The polypeptides of the invention may be membrane bound or may be in a soluble circulating form. Soluble peptides are defined by amino acid sequence wherein the sequence comprises the polypeptide sequence lacking transmembrane domains.

The polypeptides of the present invention may exist as a membrane bound receptor having a transmembrane region and an intra- and extracellular region or they may exist in soluble form wherein a transmembrane domain is lacking. One example of such a form of the VR2 receptor is the full-length VR2 polypeptide shown in FIG. 1 (SEQ ID NO:2) which contains, transmembrane, intracellular and extracellular domains. Thus, this form of the VR2 polypeptide appears to be integrated in the plasma membrane of cells which express this polypeptide.

The polypeptides of the present invention are preferably provided in an isolated form. By “isolated polypeptide”, is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and contained within a recombinant host cell would be considered “isolated” for purposes of the present invention. Also intended as an “isolated polypeptide” are polypeptides that have been purified, partially or substantially, from a recombinant host. For example, recombinantly produced versions of the VR2 polypeptides can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988).

Polypeptide fragments of the present invention include polypeptides comprising or alternatively, consisting of, an amino acid sequence contained in SEQ ID NO:2, encoded by the cDNA contained in the deposited clone, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone, or shown in FIGS. 1A-1D (SEQ ID NO:1) or the complementary strand thereto. Protein fragments may be “free-standing,” or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments that comprise or alternatively, consist of from about amino acid residues: 1 to 50, 51 to 100, 101 to 150, 151 to 200, 201 to 250, 251 to 300, 301 to 350, 321 to 333, 351 to 400, 401 to 450, 451 to 500, 501 to 550, 551 to 600, 576 to 606, 601 to 650, 651 to 700, 701 to 750, 751 to 800, 801 to 850 and/or 851 to 889 of SEQ ID NO:2. Moreover, polypeptide fragments can be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175 or 200 amino acids in length.

In additional embodiments, the polypeptide fragments of the invention comprise, or alternatively consist, of one or more VR2 receptor domains. In particular embodiments, such polypeptide fragments comprise, or alternatively, consist of (a) N-terminal intracellular domain 1 (amino acid residues M-1 to about N-520 of SEQ ID NO:2); (b) ankyrin repeat domain 1 (within N-terminal intracellular domain; amino acid residues from about R-288 to about C-320 of SEQ ID NO:2); (c) ankyrin repeat domain 2 (within N-terminal intracellular domain, amino acid residues from about F-334 to about A-366 of SEQ ID NO:2); (d) ankyrin repeat domain 3 (within N-terminal intracellular domain; (e) amino acid residues from about Q-419 to about H-449 of SEQ ID NO:2); (f) transmembrane domain 1 (amino acid residues from about F-517 to about H-537 of SEQ ID NO:2); (g) extracellular domain 1 (amino acid residues from about Q-538 to I562 of SEQ ID NO:2); (h) transmembrane domain 2 (about L-563 to about Y-578 of SEQ ID NO:2); (i) intracellular domain 2 (amino acid residues from about F-579 to about D-592 of SEQ ID NO:2); (n) transmembrane domain 3 (amino acid residues from about S-593 to about F-614 of SEQ ID NO:2); (k) extracellular domain 2 (amino acid residues from about L-615 to about V-625 of SEQ ID NO:2); (1) transmembrane domain 4 (amino acid residues from about S-626 to about I652 of SEQ ID NO:2); (m) intracellular domain 3 (amino acid residues from about Q-653 to about D-659 of SEQ ID NO:2); (n) transmembrane domain 5 (amino acid residues from about L-660 to about V-679 of SEQ ID NO:2); (o) extracellular domain 3 (amino acid residues from about S-680 to about N-711 of SEQ ID NO:2); (p) pore loop (amino acid residues from about G-712 to about G-733 of SEQ ID NO:2); (q) extracellular domain 4 (amino acid residues from about E-734 to about H-742 of SEQ ID NO:2); (r) transmembrane domain 6 (amino acid residues from about F-743 to about S-771 of SEQ ID NO:2); (s) C-terminal intracellular domain 4 (amino acid residues from about E-772 to about N-889 of SEQ ID NO:2); or (t) any combination of polypeptides (a)-(s).

Among the especially preferred fragments of the invention are fragments characterized by structural or functional attributes of VR2. Such fragments include amino acid residues that comprise alpha-helix and alpha-helix forming regions (“alpha-regions”), beta-sheet and beta-sheet-forming regions (“beta-regions”), turn and turn-forming regions (“turn-regions”), coil and coil-forming regions (“coil-regions”), hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, surface forming regions, and high antigenic index regions (i.e., containing four or more contiguous amino acids having an antigenic index of greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) of full-length VR2 (SEQ ID NO:2). Certain preferred regions are those set out in FIG. 3 and include, but are not limited to, regions of the aforementioned types identified by analysis of the amino acid sequence depicted in FIGS. 1A-1D (SEQ ID NO:2), such preferred regions include; Garnier-Robson predicted alpha-regions, beta-regions, turn-regions, and coil-regions; Chou-Fasman predicted alpha-regions, beta-regions, turn-regions, and coil-regions; Kyte-Doolittle predicted hydrophilic and hydrophobic regions; Eisenberg alpha and beta amphipathic regions; Emini surface-forming regions; and Jameson-Wolf high antigenic index regions, as predicted using the default parameters of these computer programs. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In specific embodiments, polypeptide fragments of the invention comprise, or alternatively consist of, amino acid residues: 231 to 253, 289 to 297, 305 to 329, 321 to 332, 332 to 347, 370 to 385, 402 to 443, 576 to 590, 576 to 613, 590 to 599, 591 to 600, 600 to 613; 606 to 614, 637 to 654, 723 to 735, 772 to 798, and/or 804 to 839 as depicted in FIGS. 1A-1D (SEQ ID NO:2). Polynucleotides encoding these polypeptides are also encompassed by the invention.

The invention also provides polypeptides comprising epitope-bearing portions of the polypeptides of the invention. The epitopes of these polypeptide portions are an immunogenic or antigenic epitopes of the polypeptides described herein. An “immunogenic epitope” is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an “antigenic epitope.” The number of immunogenic epitopes of a polypeptide generally is less than the number of antigenic epitopes. See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).

As to the selection of polypeptides bearing an antigenic epitope (i.e., that contain a region of a polypeptide to which an antibody can bind), it is well known in that art that relatively short synthetic polypeptides that mimic part of a polypeptide sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked polypeptide. See, for instance, Sutcliffe et al., Science 219:660-666 (1983). Polypeptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a polypeptide, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact polypeptides (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals.

Antigenic epitope-bearing polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. See, for instance, Wilson et al., Cell 37:767-778 (1984) at 777. Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least four, at least seven, more preferably at least nine, and most preferably between at least about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.

Non-limiting examples of antigenic polypeptides that can be used to generate VR2 receptor-specific antibodies include: a polypeptide comprising amino acid residues from: C-9 to L-24; from A-28 to C-37; from W-46 to H-65; from T-83 to P-134; from E-139 to P-178; from R-181 to N-207; from V-209 to G-219; from E-222 to L-246; from L-251 to N-258; from Q-266 to P-274; from T-283 to S-291; from I-297 to Q-303; from V-309 to A-313; from R-318 to T-330; from C-344 to D-349; from L-355 to A-362; from Q-365 to N-372; from S-382 to E-387; from Q-411 to E-434; from R-442 to G-446; from L-450 to T-455; from A-470 to V-480; from C-488 to R-495; from P-539 to N-554; from E-684 to Q-714; from R-804 to A-809; from G-816 to E-833; and from E-840 to Y-880, as depicted in FIGS. 1A-1D (SEQ ID NO:2). In a preferred embodiment, the polypeptide fragment of the invention comprises amino acid residues V-309 to A-313 as depicted in FIGS. 1A-1D (SEQ ID NO:2). In further preferred embodiments, polypeptide fragments of the invention compose 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 of the above recited VR2 antigenic regions. As indicated above, the inventors have determined that the above polypeptide fragments are antigenic regions of the VR2 polypeptide.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means. Houghten, R. A. (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA 82:5131-5135. This “Simultaneous Multiple Peptide Synthesis (SMPS)” process is further described in U.S. Pat. No. 4,631,211 to Houghten et al. (986).

As one of skill in the art will appreciate, VR2 polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EPA 394,827; Traunecker et al., Nature 331:84-86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than the monomeric VR2 receptor polypeptides or polypeptide fragments alone (Fountoulakis et al., J. Biochem 270:3958-3964 (1995)).

For many proteins, including the extracellular domain of a membrane associated protein, it is known in the art that one or more amino acids may be deleted from the N-terminus or C-terminus without substantial loss of biological function. However, even if deletion of one or more amino acids from the N-terminus or C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other VR2 functional activities may still be retained. For example, in many instances, the ability of the shortened protein to induce and/or bind to antibodies which recognize VR2 (preferably antibodies that bind specifically to VR2) will be retained irrespective of the size or location of the deletion. Whether a particular polypeptide lacking N-terminal and/or C-terminal residues of a complete protein retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

In one embodiment, the present invention further provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of the VR2 polypeptide depicted in FIGS. 1A-1D (SEQ ID NO:2) or encoded by the cDNA of the deposited clone. Particularly, in one embodiment, N-terminal deletions of the VR2 polypeptide can be described by the general formula m to 889, where m is an integer from 1 to 888 corresponding to the position of amino acid identified in SEQ ID NO:2 and preferably, corresponds to one of the N-terminal amino acid residues identified in the N-terminal deletions specified herein. In specific embodiments, N-terminal deletions of the VR2 polypeptide of the invention comprise, or alternatively, consist of, amino acid residues: V-2 to N-889; S-3 to N-889; L-4 to N-889; W-5 to N-889; W-6 to N-889; L-7 to N-889; A-8 to N-889; C-9 to N-889; P-10 to N-889; D-11 to N-889; R-12 to N-889; G-13 to N-889; E-14 to N-889; L-15 to N-889; S-16 to N-889; S-17 to N-889; R-18 to N-889; S-19 to N-889; P-20 to N-889; P-21 to N-889; C-22 to N-889; R-23 to N-889; L-24 to N-889; A-25 to N-889; R-26 to N-889; W-27 to N-889; A-28 to N-889; E-29 to N-889; G-30 to N-889; D-31 to N-889; R-32 to N-889; E-33 to N-889; T-34 to N-889; R-35 to N-889; T-36 to N-889; C-37 to N-889; L-38 to N-889; L-39 to N-889, E-40 to N-889; L-41 to N-889; S-42 to N-889; A-43 to N-889; Q-44 to N-889; S-45 to N-889; W-46 to N-889; G-47 to N-889; G-48 to N-889; R-49 to N-889; F-50 to N-889; R-51 to N-889; R-52 to N-889; S-53 to N-889; S-54 to N-889; A-55 to N-889; V-56 to N-889; S-57 to N-889; T-58 to N-889; G-59 to N-889; S-60 to N-889; P-61 to N-889; S-62 to N-889; R-63 to N-889; L-64 to N-889; H-65 to N-889; F-66 to N-889; L-67 to N-889; P-68 to N-889; Q-69 to N-889; P-70 to N-889; L-71 to N-889; L-72 to N-889; L-73 to N-889; R-74 to N-889; S-75 to N-889; S-76 to N-889; G-77 to N-889; I-78 to N-889; P-79 to N-889; A-80 to N-889; A-81 to N-889; A-82 to N-889; T-83 to N-889; P-84 to N-889; W-85 to N-889; P-86 to N-889; Q-87 to N-889; P-88 to N-889; A-89 to N-889; G-90 to N-889; L-91 to N-889; Q-92 to N-889; S-93 to N-889; G-94 to N-889; Q-95 to N-889; H-96 to N-889; R-97 to N-889; R-98 to N-889; A-99 to N-889; R-100 to N-889; G-101 to N-889; R-102 to N-889; K-103 to N-889; T-104 to N-889; G-105 to N-889; P-106 to N-889; L-107 to N-889; T-108 to N-889; S-109 to N-889; P-110 to N-889; S-111 to N-889; A-112 to N-889; Q-113 to N-889; R-114 to N-889; S-115 to N-889; W-116 to N-889; L-117 to N-889; D-118 to N-889; R-119 to N-889; A-120 to N-889; M-121 to N-889; P-122 to N-889; P-123 to N-889; P-124 to N-889; P-125 to N-889; R-126 to N-889; M-127 to N-889; T-128 to N-889; S-129 to N-889; P-130 to N-889; S-131 to N-889; S-132 to N-889; S-133 to N-889; P-134 to N-889; V-135 to N-889; F-136 to N-889; R-137 to N-889; L-138 to N-889; E-139 to N-889; T-140 to N-889; L-141 to N-889; D-142 to N-889; G-143 to N-889; G-144 to N-889; Q-145 to N-889; E-146 to N-889; D-147 to N-889; G-148 to N-889; S-149 to N-889; E-150 to N-889; A-151 to N-889; D-152 to N-889; R-153 to N-889; G-154 to N-889; K-155 to N-889; L-156 to N-889; D-157 to N-889; F-158 to N-889; G-159 to N-889; S-160 to N-889; G-161 to N-889; L-162 to N-889; P-163 to N-889; P-164 to N-889; M-165 to N-889; E-166 to N-889; S-167 to N-889; Q-168 to N-889; F-169 to N-889; Q-170 to N-889; G-171 to N-889; E-172 to N-889; D-173 to N-889; R-174 to N-889; K-175 to N-889; F-176 to N-889; A-177 to N-889; P-178 to N-889; Q-179 to N-889; I-180 to N-889; R-181 to N-889; V-182 to N-889; N-183 to N-889; L-184 to N-889; N-185 to N-889, Y-186 to N-889; R-187 to N-889; K-188 to N-889; G-189 to N-889; T-190 to N-889; G-191 to N-889; A-192 to N-889; S-193 to N-889; Q-194 to N-889; P-1 95 to N-889; D-196 to N-889; P-197 to N-889; N-198 to N-889; R-199 to N-889; F-200 to N-889; D-201 to N-889; R-202 to N-889; D-203 to N-889; R-204 to N-889; L-205 to N-889; F-206 to N-889; N-207 to N-889; A-208 to N-889; V-209 to N-889; S-210 to N-889; R-211 to N-889; G-212 to N-889; V-213 to N-889; P-214 to N-889; E-215 to N-889; D-216 to N-889; L-217 to N-889; A-218 to N-889; G-219 to N-889; L-220 to N-889; P-221 to N-889; E-222 to N-889; Y-223 to N-889; L-224 to N-889; S-225 to N-889; K-226 to N-889; T-227 to N-889; S-228 to N-889; K-229 to N-889; Y-230 to N-889; L-231 to N-889; T-232 to N-889; D-233 to N-889; S-234 to N-889; E-235 to N-889, Y-236 to N-889; T-237 to N-889; E-238 to N-889; G-239 to N-889; S-240 to N-889; T-241 to N-889; G-242 to N-889; K-243 to N-889; T-244 to N-889; C-245 to N-889; L-246 to N-889; M-247 to N-889; K-248 to N-889; A-249 to N-889; V-250 to N-889; L-251 to N-889; N-252 to N-889; L-253 to N-889; K-254 to N-889; D-255 to N-889; G-256 to N-889; V-257 to N-889; N-258 to N-889; A-259 to N-889; C-260 to N-889; I-261 to N-889; L-262 to N-889; P-263 to N-889; L-264 to N-889; L-265 to N-889; Q-266 to N-889; I-267 to N-889; D-268 to N-889; R-269 to N-889; D-270 to N-889; S-271 to N-889; G-272 to N-889; N-273 to N-889; P-274 to N-889; Q-275 to N-889; P-276 to N-889; L-277 to N-889; V-278 to N-889; N-279 to N-889; A-280 to N-889; Q-281 to N-889; C-282 to N-889; T-283 to N-889; D-284 to N-889; D-285 to N-889; Y-286 to N-889; Y-287 to N-889; R-288 to N-889; G-289 to N-889; H-290 to N-889; S-291 to N-889; A-292 to N-889; L-293 to N-889; H-294 to N-889; I-295 to N-889; A-296 to N-889; I-297 to N-889; E-298 to N-889; K-299 to N-889; R-300 to N-889; S-301 to N-889; L-302 to N-889; Q-303 to N-889; C-304 to N-889; V-305 to N-889; K-306 to N-889; L-307 to N-889; L-308 to N-889; V-309 to N-889; E-310 to N-889; N-311 to N-889; G-312 to N-889; A-313 to N-889; N-314 to N-889; V-315 to N-889; H-316 to N-889; A-317 to N-889; R-318 to N-889; A-319 to N-889; C-320 to N-889; G-321 to N-889; R-322 to N-889; F-323 to N-889; F-324 to N-889; Q-325 to N-889; K-326 to N-889; G-327 to N-889; Q-328 to N-889; G-329 to N-889; T-330 to N-889; C-331 to N-889; F-332 to N-889; Y-333 to N-889; F-334 to N-889; G-335 to N-889; E-336 to N-889; L-337 to N-889; P-338 to N-889; L-339 to N-889; S-340 to N-889; L-341 to N-889; A-342 to N-889; A-343 to N-889; C-344 to N-889; T-345 to N-889; K-346 to N-889; Q-347 to N-889; W-348 to N-889; D-349 to N-889; V-350 to N-889; V-351 to N-889; S-352 to N-889; Y-353 to N-889; L-354 to N-889; L-355 to N-889; E-356 to N-889; N-357 to N-889; P-358 to N-889; H-359 to N-889; Q-360 to N-889; P-361 to N-889; A-362 to N-889; S-363 to N-889; L-364 to N-889; Q-365 to N-889; A-366 to N-889; T-367 to N-889; D-368 to N-889; S-369 to N-889; Q-370 to N-889; G-371 to N-889; N-372 to N-889; T-373 to N-889; V-374 to N-889; L-375 to N-889; H-376 to N-889; A-377 to N-889; L-378 to N-889; V-379 to N-889; M-380 to N-889; I-381 to N-889; S-382 to N-889; D-383 to N-889; N-384 to N-889; S-385 to N-889; A-386 to N-889; E-387 to N-889; N-388 to N-889; I-389 to N-889; A-390 to N-889; L-391 to N-889; V-392 to N-889; T-393 to N-889; S-394 to N-889; M-395 to N-889; Y-396 to N-889; D-397 to N-889; G-398 to N-889; L-399 to N-889; L-400 to N-889; Q-401 to N-889; A-402 to N-889; G-403 to N-889; A-404 to N-889; R-405 to N-889; L-406 to N-889; C-407 to N-889; P-408 to N-889; T-409 to N-889; V-410 to N-889; Q-411 to N-889; L-412 to N-889; E-413 to N-889; D-414 to N-889; I-415 to N-889; R-416 to N-889; N-417 to N-889; L-418 to N-889; Q-419 to N-889; D-420 to N-889; L-421 to N-889; T-422 to N-889; P-423 to N-889; L-424 to N-889; K-425 to N-889; L-426 to N-889; A-427 to N-889; A-428 to N-889; K-429 to N-889; E-430 to N-889; G-431 to N-889; K-432 to N-889; I-433 to N-889; E-434 to N-889; I-435 to N-889; F-436 to N-889; R-437 to N-889; H-438 to N-889; I-439 to N-889; L-440 to N-889; Q-441 to N-889; R-442 to N-889; E-443 to N-889, F-444 to N-889; S-445 to N-889; G-446 to N-889; L-447 to N-889; S-448 to N-889; H-449 to N-889; L-450 to N-889; S-451 to N-889; R-452 to N-889; K-453 to N-889; F-454 to N-889; T-455 to N-889; E-456 to N-889; W-457 to N-889; C-458 to N-889; Y-459 to N-889; G-460 to N-889; P-461 to N-889; V-462 to N-889; R-463 to N-889; V-464 to N-889; S-465 to N-889; L-466 to N-889; Y-467 to N-889; D-468 to N-889; L-469 to N-889; A-470 to N-889; S-471 to N-889; V-472 to N-889; D-473 to N-889; S-474 to N-889; C-475 to N-889; E-476 to N-889; E-477 to N-889; N-478 to N-889; S-479 to N-889; V-480 to N-889; L-481 to N-889; E-482 to N-889; I-483 to N-889; I-484 to N-889; A-485 to N-889; F-486 to N-889; H-487 to N-889; C-488 to N-889; K-489 to N-889; S-490 to N-889; P-491 to N-889; H-492 to N-889; R-493 to N-889; H-494 to N-889; R-495 to N-889; M-496 to N-889; V-497 to N-889; V-498 to N-889; L-499 to N-889; E-500 to N-889; P-501 to N-889; L-502 to N-889; N-503 to N-889; K-504 to N-889; L-505 to N-889; L-506 to N-889; Q-507 to N-889; A-508 to N-889; K-509 to N-889; W-510 to N-889; D-511 to N-889; L-512 to N-889; L-513 to N-889; I-514 to N-889; P-515 to N-889; K-516 to N-889; F-517 to N-889; F-518 to N-889; L-519 to N-889; N-520 to N-889; F-521 to N-889; L-522 to N-889; C-523 to N-889; of SEQ ID NO:2. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Further embodiments of the invention are directed to C-terminal deletions of the VR2 polypeptide described by the general formula 1 to n, where n is an integer from 2-888 corresponding to the position of amino acid residue identified in SEQ ID NO:2 and preferably, corresponds to one of the C-terminal amino acid residues identified in the C-terminal deletions specified herein. In specific embodiments, C terminal deletions of the VR2 polypeptide of the invention comprise, or alternatively, consist of, amino acid residues: M-1 to S-888; M-1 to Q-887; M-1 to L-886; M-1 to L-885; M-1 to Q-884; M-1 to V-883; M-1 to P-882; M-1 to V-881; M-1 to Y-880; M-1 to N-879; M-1 to E-878; M-1 to E-877; M-1 to S-876; M-1 to A-875; M-1 to G-874; M-1 to D-873; M-1 to E-872; M-1 to D-871; M-1 to E-870; M-1 to K-869; M-1 to P-868; M-1 to P-867; M-1 to S-866; M-1 to A-865; M-1 to L-864; M-1 to V-863; M-1 to P-862; M-1 to N-861; M-1 to E-860; M-1 to L-859; M-1 to T-858; M-1 to R-857; M-1 to P-856; M-1 to V-855; M-1 to G-854; M-1 to A-853, M-1 to G-852; M-1 to S-851; M-1 to P-850; M-1 to D-849; M-1 to E-848; M-1 to C-847; M-1 to L-846; M-1 to T-845; M-1 to P-844; M-1 to L-843; M-1 to T-842; M-1 to Q-841; M-1 to E-840; M-1 to W-839; M-1 to S-838; M-1 to A-837; M-1 to W-836; M-1 to N-835; M-1 to V-834; M-1 to E-833, M-1 to E-832; M-1 to V-831; M-1 to R-830; M-1 to F-829; M-1 to C-828; M-1 to W-827; M-1 to R-826; M-1 to E-825; M-1 to D-824; M-1 to P-823; M-1 to S-822; M-1 to G-821; M-1 to D-820; M-1 to P-819; M-1 to K-818; M-1 to T-817; M-1 to G-816; M-1 to V-815; M-1 to T-814; M-1 to L-813; M-1 to M-812; M-1 to V-811; M-1 to G-810; M-1 to A-809; M-1 to R-808; M-1 to Q-807; M-1 to K-806; M-1 to K-805; M-1 to R-804; M-1 to C-803; M-1 to W-802; M-1 to W-801; M-1 to Y-800; M-1 to G-799; M-1 to N-798; M-1 to E-797; M-1 to M-796; M-1 to E-795; M-1 to L-794; M-1 to V-793; M-1 to S-792; M-1 to I-791; M-1 to A-790; M-1 to K-789; M-1 to Q-788; M-1 to L-787; M-1 to K-786; M-1 to W-785; M-1 to I-784; M-1 to S-783; M-1 to W-782; M-1 to S-781; M-1 to D-780; M-1 to T-779; M-1 to A-778; M-1 to V-777; M-1 to S-776; M-1 to N-775; M-1 to V-774; M-1 to T-773; M-1 to E-772; M-1 to S-771; M-1 to M-770; M-1 to L-769; M-1 to A-768; M-1 to I-767; M-1 to L-766; M-1 to M-765; of SEQ ID NO:2. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Further embodiments of the invention are directed to polypeptide fragments comprising, or alternatively, consisting of, amino acids described by the general formula m to n, where m and n are integers corresponding to any one of the amino acid residues specified above for these symbols, respectively.

It will be recognized in the art that some amino acid sequences of the VR2 receptors can be varied without significant effect to the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity. Thus, the invention further includes variations of the VR2 receptors which show substantial VR2 receptor activity or which include regions of VR2 proteins such as the polypeptide portions discussed below. Such mutants include deletions, insertions, inversions, repeats, and type substitutions. As indicated above, guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie et al, “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247:1306-1310 (1990).

Thus, the fragment, derivative or analog of the polypeptide of FIGS. 1A-1D (SEQ ID NO:2), or that encoded by the deposited cDNA, may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the VR2 polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the full length polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the VR2 polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

Of particular interest are substitutions of charged amino acids with another charged amino acid and with neutral or negatively charged amino acids. The latter results in polypeptides with reduced positive charge to improve the characteristics of the VR2 polypeptides. The prevention of aggregation is highly desirable. Aggregation of polypeptides not only results in a loss of activity but can also be problematic when preparing pharmaceutical formulations, because they can be immunogenic. (Pinckard et al., Clin. Exp. Immunol . 2:331-340 (1967); Robbins et al., Diabetes 36:838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993)).

The replacement of amino acids can also change the selectivity of binding to cell surface receptors. For example, Ostade et al., Nature 361:266-268 (1993)) describes certain mutations resulting in selective binding of TNF-a to only one of the two known types of TNF receptors. Thus, the VR2 receptors of the present invention may include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation.

As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 1).

TABLE 1
Conservative Amino Acid Substitutions
Aromatic    Phenylalanine
            Tryptophan
            Tyrosine
Hydrophobic Leucine
            Isoleucine
            Valine
Polar       Glutamine
            Asparagine
Basic       Arginine
            Lysine
            Histidine
Acidic      Aspartic Acid
            Glutamic Acid
Small       Alanine
            Serine
            Threonine
            Methionine
            Glycine

In specific embodiments, the number of substitutions, additions or deletions in the amino acid sequence of FIGS. 1A-1D (SEQ ID NO:2) and/or any of the polypeptide fragments described herein (e.g., the extracellular domains or intracellular domains) is 100, 90, 80, 75, 70, 60, 50, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 150-100, 100-50, 50-20, 20-10, 5-10, 1-5, 1-3 or 1-2.

Amino acids in the VR2 polypeptides of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as receptor binding in vitro, or in vitro ion (e.g., calcium) flux. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol . 224:899-904 (1992) and de Vos et al., Science 255:306-312 (1992)).

The polypeptides of the present invention also include the polypeptide encoded by the deposited cDNA; the polypeptide of FIGS. 1A-1D (SEQ ID NO:2); the polypeptides of FIGS. 1A-1D (SEQ ID NO:2) minus the N-terminal methionine; the polypeptide sequence of any of the VR2 domains described herein; the polypeptide sequence of FIGS. 1A-1D (SEQ ID NO:2) minus a portion, or all of, one or more of the extracellular domains, transmembrane domains, intracellular domains, ankyrin repeat domains, and pore loop of the VR2 receptor shown in FIGS. 1A-1D (SEQ ID NO:2); and polypeptides which are at least 80% identical, more preferably at least 85%, 90% or 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to the polypeptides described above, and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.

By a polypeptide having an amino acid sequence at least, for example, 95% “identical” to a reference amino acid sequence of a VR2 polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of a VR2 receptor. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in FIGS. 1A-1D (SEQ ID NO:2), the amino acid sequence encoded by the deposited cDNA clone, or fragments thereof, can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present 20 invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

In a specific embodiment, the identity between a reference (query) sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, is determined using the FASTDB computer program based on the algorithm of Brutlag et al, Comp. App. Biosci . 6:237-245 (1990)). Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter. According to this embodiment, if the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction is made to the results to take into consideration the fact that the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. A determination of whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of this embodiment. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence. For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of this embodiment.

The polypeptides of the present invention have uses which include, but are not limited to, molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art.

Detection of Disease States

Cells which express the VR2 polypeptides and are believed to have a potent cellular response to vanilloid receptor family ligand include, for example, hematopoietic cells, blood cells and cells and tissue of the immune system. In addition, Northern blots revealed an approximately 2.5 to 3.5 kb mRNA observed most abundantly in spleen, lymph node, peripheral blood leukocytes, and lung, and next highest levels were observed in thymus, heart, placenta, brain, bone marrow, and fetal liver. By “a cellular response to a vanilloid receptor family ligand” is intended any genotypic, phenotypic, and/or morphologic change to a cell, cell line, tissue, tissue culture or patient that is induced by a vanilloid receptor family ligand or stimuli (e.g., heat). As indicated, such cellular responses include not only normal physiological responses to vanilloid receptor family ligands or stimuli (e.g., heat), but also diseases associated with aberrant pain sensitivity, and aberrant cell secretion, activation, survival, migration and differentiation.

Thus, it is believed that certain tissues in mammals with certain diseases (e.g., pain syndromes and insensitivities, diseases associated with increased or decreased cell survival, secretion, activation, migration, differentiation, and proliferation; inflammatory diseases; ischemia; aberrant host defense; aberrant immune surveillance; arthritis; autoimmunity; (e.g., lupus erythematosus (SLE), rheumatoid arthritis (RA), insulin-dependent diabetes, multiple sclerosis (MS), giant cell arteritis, polyarteritis nodosa, myasthenia gravis, scleroderma, and graft versus host disease): immune dysfunction; and allergy), express significantly altered (e.g., enhanced or decreased) levels of the VR2 polypeptide and mRNA encoding the VR2 polypeptide when compared to a corresponding “standard” mammal, i.e., a mammal of the same species not having the disease. Diseases associated with increased cell survival, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors); autoimmune disorders (such as systemic lupus erythematosus and immune-related glomerulonephritis rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), information graft v. host disease, acute graft rejection, and chronic graft rejection. Diseases associated with decreased cell survival, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration); myelodysplastic syndromes (such as aplastic anemia), ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Further, it is believed that altered levels of the VR2 polypeptide can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) from mammals with the disorder when compared to sera from mammals of the same species not having the disorder. Thus, the invention provides a diagnostic method useful during diagnosis, which involves assaying the expression level of the gene encoding the VR2 polypeptide in mammalian cells or body fluid and comparing the gene expression level with a standard VR2 gene expression level, whereby an increase or decrease in the gene expression level over the standard is indicative of the disease.

By “assaying” the expression level of the gene encoding the VR2 polypeptide” is intended qualitatively or quantitatively measuring or estimating the level of the VR2 polypeptide or the level of the mRNA encoding the VR2 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute polypeptide or mRNA level) or relatively (e.g., by comparing to the VR2 polypeptide level or mRNA level in a second biological sample). Preferably, the VR2 receptor protein level or mRNA level in the first biological sample is measured or estimated and compared to a standard VR2 receptor protein level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disease state. As will be appreciated in the art, once a standard VR2 receptor protein level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By “biological sample” is intended any biological sample obtained from an individual, cell line, tissue culture, or other source which contains VR2 receptor protein or mRNA. Biological samples include mammalian body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid), and spleen, lymph node, peripheral blood leukocytes, lung, thymus, heart, placenta, brain, bone marrow, and fetal liver, and other tissues. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

Where a diagnosis has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting altered VR2 gene expression will experience a worse clinical outcome relative to patients expressing the gene at a normal level.

Nucleic acids for diagnosis may be obtained from a biological sample of a subject, such as from blood, urine, saliva, tissue biopsy or autopsy material, using techniques known in the art. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled VR2 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers et al., Science 230:1242 (1985)). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton et al., Proc. Natl. Acad. Sci. USA 85:4397-4401 (1985)). In another embodiment, an array of oligonucleotides probes comprising VR2 polynucleotide sequences or fragments thereof, can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example, Chee et al., Science 274:610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to specific diseases through detection of mutation in the VR2 gene by the methods described herein or otherwise known in the art.

In addition, specific diseases can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of VR2 polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art, which include, but are not limited to, Northern blot analysis, (Harada et al., Cell 63:303-312 (1990)), S1 nuclease mapping (Fijita et al., Cell 49:357-367 (1987)), RNAse protection, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR) (Makino et al., Technique 2:295-301 (1990), reverse transcription in combination with the ligase chain reaction (RT-LCR) and other hybridization methods.

Assaying VR2 polypeptide levels in a biological sample can be by any techniques known in the art, which include, but are not limited to, radioimmunoassays, competitive-binding assays, Western Blot analysis and enzyme linked immunosorbent assays (ELISAs) and other antibody-based techniques. For example, VR2 polypeptide expression in tissues can be studied with classical immunohistological methods (Jalkanen et al., J. Cell. Biol . 101:976-985 (1985); Jalkanen et al., J. Cell. Biol . 105:3087-3096 (1987)).

Suitable labels are known in the art and include enzyme labels, such as, Glucose oxidase, and radioisotopes, such as iodine ( 125 I, 121 I), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium ( 112 In), and technetium ( 99m Tc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Antibodies

The VR2 polypeptides, their variants, fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Thus, as used herein, the term “antibody” (Ab) or “monoclonal antibody” (mAb) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and Fab (ab′) fragments) which are capable of specifically binding to VR2 receptor protein. Fab and F(ab′) fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., J. Nucl. Med . 24:316-325 (1983)). Thus, these fragments are preferred. Various procedures known in the art may be used for the production of the antibodies and fragments described herein.

Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.

The antibodies of the invention may be prepared by any of a variety of techniques known in the art using VR2 receptor immunogens of the present invention. Such VR2 receptor immunogens include the full-length VR2 polypeptide shown in FIGS. 1A-1D (SEQ ID NO:2) and polypeptide fragments of the receptor comprising the ligand binding domain, all or a portion of one or more of the extracellular domains, transmembrane domains, intracellular domains, ankyrin domains, and pore loop of the VR2 receptors, or any combination thereof. For example, cells expressing the VR2 receptor polypeptide, or an antigenic fragment thereof, can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of VR2 polypeptide is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, Nature 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today 4:72(1983)), the EBV-hybridomatechniqueto produce human monoclonal antibodies (Cole, et al., in: Monoclonal Antibodies and Cancer Therapy , Alan R. Liss, Inc., pp. 77-96 (1985)). In general, such procedures involve immunizing an animal (preferably a mouse) with a VR2 receptor protein antigen or, more preferably, with a VR2 receptor protein-expressing cell. Suitable cells can be recognized by their capacity to bind anti-VR2 receptor protein antibody. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 μg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the American Type Culture Collection, Manassas, Va. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al., Gastroenterology 80:225-232(1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the VR2 receptor protein antigen.

Techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention. Also, transgenic mice may be used to express humanized antibodies to immunogenic polypeptide products of this invention.

For in vivo use of anti-TNF-gamma in humans, it may be preferable to use “humanized” chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art (Morrison, Science 229:1202 (1985); Oi, et al., BioTechniques 4:214 (1986); Cabilly, et al., U.S. Pat. No. 4,816,567; Taniguchi, et al., EP 171496; Morrison, et al., EP 173494; Neuberger, et al., WO 8601533; Robinson, et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).

Antibodies of the invention can be used in methods known in the art relating to the localization and activity of the polypeptide sequences of the invention, e.g., for imaging these polypeptides, measuring levels thereof in appropriate physiological samples, etc. The antibodies also have use in immunoassays and in therapeutics as agonists and antagonists of VR2.

Agonists and Antagonists of VR2

In one embodiment, the present invention is directed to a method for identifying compounds that interact with (e.g., bind to) VR2 polypeptides (including, but not limited to full-length VR2, and one or more extracellular or intracellular domains of VR2). Compounds identified may be useful, for example, in modulating the activity VR2 gene products; in elaborating the biological function of VR2; in screens for identifying compounds that disrupt normal VR2 interactions; or may in themselves disrupt such interactions and therefore may have uses which include, for example, as analgesic agents regulators of hematopoiesis or as regulators of immune response.

The principle of the assays used to identify compounds that bind to VR2 involves preparing a reaction mixture of VR2 and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex which can be removed and/or detected in the reaction mixture. The VR2 polypeptide species used can vary depending upon the goal of the screening assay. For example, where agonists of the natural ligand are sought, the full length VR2, or a soluble truncated VR2 (e.g., containing one or more extracellular or intracellular domains, but in which the transmembrane domains are deleted from the molecule, a peptide corresponding to a VR2 extracellular domain or a fusion protein containing a VR2 extracellular domain fused to a polypeptide that affords advantages in the assay system (e.g., labeling, isolation of the resulting complex, etc.) can be utilized. Where compounds that interact with a VR2 intracellular domain are sought to be identified, peptides corresponding to the VR2 intracellular domain and fusion proteins containing a VR2 intracellular domain can be used.

The compounds that may be screened in accordance with the invention include, but are not limited to, soluble peptides, including but not limited to those found in random peptide libraries; (see, e.g., Lam et al., Nature 354 82-84 (1991); Houghten, R., et al., Nature 354:84-86 (1991)), cell or tissue lysates, and biological samples (e.g,. cells, tissue, sera and lymph). Such compounds may also be found in random peptide expression libraries, and genomic or cDNA expression libraries, or combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; phosphopeptides (including, but not limited to members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang et al., Cell 72:767-778 (1993)); antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab′)2 and FAb expression library fragments, and epitope-binding fragments thereof); and small organic or inorganic molecules.

Numerous experimental methods may be used to select and detect polypeptides that bind with VR2, including, but not limited to, protein affinity chromatography, affinity blotting, immunoprecipitation, cross-linking, and library based methods such as protein probing, phage display and the two-hybrid system. See generally, Phizicky et al., Microbiol. Rev . 59:94-123 (1995). Once isolated, such an VR2-binding polypeptide can be identified and can, in turn, be used, in conjunction with standard techniques, to identify polypeptides with which it interacts. For example, at least a portion of the amino acid sequence of a polypeptide that interacts with VR2 can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique. (See, e.g., Creighton, 1983, “Proteins: Structures and Molecular Principles”, W. H. Freeman & Co., N.Y., pp.34-49). The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such polypeptides. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (See, e.g., Sambrook et al., Molecular Cloning: A laboratory Manual , 2nd Edit., (1989), Cold Spring Harbor Laboratory Press; and PCR Protocols: A Guide to Methods and Applications, 1990, Innis, M. et al., eds. Academic Press, Inc., New York).

Additionally, methods may be employed which result in the simultaneous identification of genes which encode polypeptides interacting with VR2. These methods include, for example, probing expression libraries, in a manner similar to the well known technique of antibody probing of (gt11 libraries, using labeled VR2 polypeptide, such as a VR2 fusion protein wherein a VR2 domain is fused to a marker (e.g., an enzyme, fluor, luminescent protein, or dye), or an Ig-Fc domain. For example, the two-hybrid system may be used to detect interaction between VR2 and candidate proteins for which genes encoding the candidate polypeptides are available by constructing the appropriate hybrids and testing for reporter gene activity. If an interaction is detected using the two-hybrid method, deletions can be made in the DNA encoding the candidate interacting polypeptide or the VR2 polypeptide to identify a minimal domain for interaction. Alternatively, the two-hybrid system can be used to screen available organismal and/or mammalian tissue specific libraries of activation domain hybrids to identify polypeptides that bind to a VR2 polypeptide. These screens result in the immediate availability of the cloned gene for any new polypeptide identified. In addition, since multiple clones that encode overlapping regions of protein are often identified, the minimal domain for interaction may be readily apparent from the initial screen.

Assays may also be used that identify compounds which bind to VR2 gene regulatory sequences (e.g., promoter or enhancer sequences) and which may modulate VR2 gene expression. See e.g., Platt, J. Biol. Chem . 269:28558-28562 (1994), which is incorporated herein by reference in its entirety.

The screening assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring the VR2 polypeptide (e.g., fusion protein) or the test substance onto a solid phase and detecting VR2/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the VR2 reactant may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.

In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the polypeptide and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the polypeptide to be immobilized may be used to anchor the polypeptide to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for VR2 polypeptide or fusion protein or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

Alternatively, cell-based assays can be used to identify compounds that interact with VR2. Such cell-based systems can include, for example, recombinant or non-recombinant cells, such as cell lines, which express the VR2. For example spleen, lymph node, peripheral blood leukocytes, lung, thymus, heart, placenta, brain, bone marrow, and liver cells, or cell lines derived from spleen, lymph node, peripheral blood leukocytes, lung, thymus, heart, placenta, brain, bone marrow, and liver cells can be used. In addition, expression host cells (e.g., COS cells, CHO cells, HEK293 cells, fibroblasts) genetically engineered (e.g., by transfection or transduction of VR2 DNA) to express a functional VR2 and to respond to activation by the natural VR2 ligand (e.g., a vanilloid compound, such as, for example, capsaicin), e.g., as measured by a chemical or phenotypic change, induction of another host cell gene, change in ion flux (e.g., Ca +2 ), etc., can be used as an end point in the assay. Interaction of the test compound with, for example, one or more VR2 extracellular domains expressed by the host cell can be determined by comparison or competition with VR2 ligands (e.g., vanilloid compounds such as, capsaicin), by the ability to induce a VR2 mediated cellular response (e.g., ion (e.g., Ca +2 ) flux), and other techniques known in the art. (See generally Caterina et al., Nature 389:816-824 (1997) which is herein incorporated by reference in its entirety). Thus, the present invention also provides a screening method for identifying compounds capable eliciting a cellular response induced by VR2 receptors, which involves contacting cells which express VR2 with the candidate compound, and comparing the cellular response to that observed in absence of the candidate compound (i.e., the standard); whereby, an increased cellular response over the standard indicates that the compound is an agonist.

Cellular responses that may be assayed according to this embodiment, include, but are not limited to alterations in the expression of the VR2 gene, e.g., by assaying cell lysates for VR2 mRNA transcripts (e.g., by Northern analysis) or for VR2 expressed in the cell; compounds which regulate or modulate expression of the VR2 gene are good candidates as therapeutics. Additionally, activity of the VR2 signal transduction pathway itself(e.g., cation flux, such as calcium flux) can be routinely assayed using techniques known in the art (see, e.g., Caterina et al., Nature 389:816-824 (1997), the contents of which are herein incorporated by reference in its entirety).

In another embodiment, the present invention is directed to a method for inhibiting an activity (e.g., ion flux (e.g., Ca +2 ) flux), of VR2 induced by a VR2 ligand or VR2 stimulus (e.g., temperature), which involves administering to a cell which expresses a VR2 polypeptide, an effective amount of a VR2 receptor ligand, analog or an antagonist capable of decreasing VR2 mediated signaling. Preferably, VR2 receptor mediated signaling is decreased to treat a disease wherein increased ion flux is exhibited. An antagonist can include soluble forms of the VR2 and antibodies directed against the VR2 polypeptides which block VR2 receptor mediated signaling. Preferably, VR2 receptor mediated signaling is decreased to treat a disease, or to decrease survival, secretion, proliferation, migration and/or differentiation of cells.

In an additional embodiment, the present invention is directed to a method for increasing an activity (e.g., ion (e.g., Ca +2 ) flux), induced by a VR2 ligand (e.g., a vanilloid, such as, capsaicin) or VR2 stimulus (e.g., heat), which involves administering to a cell which expresses a VR2 polypeptide an effective amount of an agonist capable of increasing VR2 receptor mediated signaling. Preferably, VR2 receptor mediated signaling is increased to treat a disease wherein decreased ion flux is exhibited. Agonists of the present invention include monoclonal antibodies directed against the VR2 polypeptides which stimulate VR2 receptor mediated signaling. Preferably, VR2 receptor mediated signaling is increased to treat a disease, and to increase survival, secretion, proliferation, migration, and/or differentiation of cells.

By “agonist” is intended naturally occurring and synthetic compounds capable of eliciting or enhancing ion (e.g., Ca +2 )flux mediated by VR2 polypeptides. Such agonists include agents which increase expression of VR2 receptors or increase the sensitivity of the expressed receptor. By “antagonist” is intended naturally occurring and synthetic compounds capable of inhibiting VR2 mediated ion (e.g., Ca +2 ) flux. Such antagonists include agents which decrease expression of VR2 receptors or decrease the sensitivity of the expressed receptor. Whether any candidate “agonist” or “antagonist” of the present invention can enhance or inhibit a VR2 mediated cellular response, such as, for example, ion flux, and cell proliferation, survival, and differentiation can be determined using art-known ligand/receptor cellular response assays, and ion flux assays, including those described herein.

Thus, the present invention also provides a screening method for identifying compounds capable of enhancing or inhibiting a cellular response induced by VR2 receptors. The method involves contacting cells which express VR2 polypeptides with the candidate compound in the presence of a VR2 ligand (e.g., a vanilloid compound, such as, capsaicin) or other stimulus (e.g., heat), assaying a cellular response (e.g., ion (e.g., Ca +2 ) flux), and comparing the cellular response to a standard cellular response, the standard being assayed when contact is made between the VR2 ligand and VR2, or when VR2 is exposed to the stimulus, in absence of the candidate compound; whereby, an increased cellular response over the standard indicates that the compound is an agonist of the VR2-mediated signaling pathway and a decreased cellular response over the standard indicates that the compound is an antagonist of the VR2-mediated signaling pathway. By “assaying a cellular response” is intended qualitatively or quantitatively measuring a cellular response to a candidate compound and/or a VR2 ligand or VR2 stimulus (e.g., determining or estimating an increase or decrease in ion (e.g., Ca +2 ) flux). By the invention, a cell expressing a VR2 polypeptide can be contacted with either an endogenous or exogenously administered VR2 ligand.

One such screening technique involves the use of cells which express the receptor (for example, transfected kidney-derived HEK293 cells) in a system which measures intracellular Ca +2 changes caused by receptor activation, for example, as described Caterina et al., Nature 389:816-824 (1997). For example, compounds may be contacted with a cell which expresses the VR2 polypeptide of the present invention and ion (e.g., Ca +2 ) flux, may be measured to determine whether the potential compound activates (i.e., leads to elevated ion flux) or inhibits the receptor.

Another method involves screening for compounds which inhibit activation of the receptor polypeptide of the present invention (i.e., antagonists) by determining inhibition of binding of labeled ligand to cells which have the receptor on the surface thereof. Such a method involves transfecting a eukaryotic cell with DNA encoding the VR2 polypeptide such that the cell expresses the receptor on its surface and contacting the cell with a compound in the presence of a labeled form of a VR2 ligand (e.g., a vanilloid compound, such as capsaicin). The ligand can be labeled, e.g., by radioactivity. The amount of labeled ligand bound to the receptors is measured, e.g., by measuring radioactivity of the VR2 polypeptide. If the compound binds to the receptor as determined by a reduction of labeled ligand which binds to the receptors, the binding of labeled ligand to the VR2 polypeptide is inhibited.

Soluble forms of the polypeptides of the present invention may be utilized in the ligand binding assay described above. These forms of the VR2 receptor are contacted with ligands in the extracellular medium after they are secreted. A determination is then made as to whether the secreted protein will bind to VR2 receptor ligands.

Agonists according to the present invention include compounds such as, for example, vanilloid receptor ligand peptide fragments, and neurotransmitters. Preferred agonists include VR2 polypeptide fragments of the invention and/or polyclonal and monoclonal antibodies raised against a VR2 polypeptide, or a fragment thereof.

VR2 polypeptides and polynucleotides and compounds identified as VR2 agonists or antagonists using assays described herein or otherwise known in the art, have uses which include, but are not limited to, treating diseases, regulating hematopoiesis, regulating immune responses, regulating cell survival, activation, secretion, migration and differentiation, regulating pain, and in developing analgesic agents and in furthering our understanding of pain insensitivity and pain syndromes.

Prophtylactic and Therapeutic Methods

It is to be understood that although the following discussion is specifically directed to human patients, the teachings are also applicable to any animal that expresses VR2.

As noted above, VR2 is structurally related to members of the TRP family of ion channels and shares significant homology with rat vanilloid receptor-1 which has been demonstrated to mediate influx of calcium ions into the cytoplasm of cells expressing VR2 and is believed to be involved in diverse human diseases ranging from congenital pain insensitivity to chronic pain. Thus, it is likely that VR2 is active in modulating growth regulatory activities (e.g., cell survival, secretion, differentiation and/or cell proliferation) and pain perception. Further, VR2, like VR1, might be involved in detection of noxious stimuli that accompany such conditions as inflammation and ischemia. Additionally, the expression profile of VR2 suggests that it may play a role in a broader variety of cell types than observed for VR1. Particularly, VR2 is expressed on non-neuronal cells in addition to neuronal cells, most notably hematopoietic tissue, cells and tissue of the immune system, and blood cells. Thus VR2 plays a role in regulating the flux of calcium or other cations into other cells, such as, hematopoietic cells (e.g., macrophages), and this flux is likely to result in activation, survival, proliferation, migration, and differentiation, as well as the regulation of cytokine profiles by such cells. Thus VR2 is likely to play a role in influencing various diseases or medical conditions, including, but not limited to, inflammation, host defense, immune surveillance, arthritis, MS, autoimmunity, immune dysfunction, and allergy. Additionally, VR2 appears to be expressed in other cell populations (e.g., endothelial cells, mesenchymal cells, and epithelial cells) and thus VR2 likely regulates ion flux into these cells, thereby regulating their survival, differentiation, morphology, and proliferation. Accordingly, it is likely that VR2 plays a role in other physiological or disease conditions, including, cancer, angiogenesis, wound healing, fibrosis, and tissue regeneration. Any method which neutralizes or enhances VR2 mediated signaling can be used to modulate growth regulatory activities (e.g., cell proliferation), and other activities mediated by VR2 signaling, such as, for example, pain sensitivity, inflammation, host defense, immune surveillance, arthritis, MS, autoimmunity, immune dysfunction, allergy, cancer, angiogenesis, wound healing, fibrosis, and tissue regeneration.

VR2 polynucleotides or polypeptides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) may be useful in treating disorders associated with chronic pain syndromes, congenital pain insensitivity, inflammation, and ischemia. Additionally, these compounds may be useful in treating or preventing cell death (e.g., of hematopoietic cells during processes of inflammation of tissue injury).

VR2 polypeptides or polynucleotides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, VR2 polynucleotides or polypeptides can be used as a marker or detector of a particular immune system disease or disorder.

VR2 polynucleotides or polypeptides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. As further discussed below, VR2 polypeptides, polynucleotides, and/or VR2 agonists or antagonists could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types of hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria. Additionally, VR2 polypeptides, polynucleotides and/or VR2 antagonists can be used to treat or prevent the killing of hematopoietic cells and other cells during processes of inflammation or tissue injury.

Moreover, VR2 polypeptides or polynucleotides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) can also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, VR2 polynucleotides or polypeptides could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, VR2 polynucleotides, polypeptides and/or VR2 agonists or antagonists that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting, important in the treatment of heart attacks (infarction), strokes, or scarring.

VR2 polynucleotides or polypeptides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists or VR2 antagonists as described herein) may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of VR2 polypeptides or polynucleotides and/or VR2 agonists or VR2 antagonists that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders. Examples of autoimmune disorders that can be treated or detected by VR2 include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems may also be treated by VR2 polypeptides, VR2 polynucleotides or VR2 agonists or VR2 antagonists. Moreover, VR2 can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

VR2 polynucleotides or polypeptides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and VR2 antagonists as described herein) may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of VR2 polypeptides or polynucleotides and/or VR2 agonists or antagonists that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, VR2 polypeptides or polynucleotides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and VR2 antagonists as described herein) may also be used to modulate inflammation. For example, VR2 polypeptides or polynucleotides and/or VR2 agonists and antagonists of the invention may inhibit the proliferation and differentiation of cells involved in an inflammatory response or alternatively may be involved in killing of hematopoietic cells during processes of inflammation or tissue injury. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1). Additionally, these molecules may be used to treat or prevent killing of hematopoietic cells and/or other cells during processes of inflammation or tissue injury.

VR2 polypeptides or polynucleotides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) can be used to treat or detect hyperproliferative disorders, including neoplasms. VR2 polypeptides or polynucleotides and/or VR2 agonists or antagonists, may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, VR2 polypeptides or polynucleotides and/or VR2 agonists or antagonists may proliferate other cells which can inhibit the hyperproliferative disorder. For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists include, but are not limited to, neoplasms located in the: blood, abdomen, bone, lung, breast, digestive system, liver, pancreas, prostate, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, hematopoietic tissue, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

VR2 polypeptides or polynucleotides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, VR2 polypeptides or polynucleotides and/or VR2 agonists or antagonists may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated by VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists. Examples of viruses, include, but are not limited to, the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Bimaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. VR2 polypeptides or polynucleotides and/or VR2 agonists or antagonists can be used to treat any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated by VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists include, but are not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Kiebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. VR2 polypeptides or polynucleotides and/or VR2 agonists or antagonists can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists include, but are not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. VR2 polypeptides or polynucleotides and/or VR2 agonists or antagonists can be used to treat or detect any of these symptoms or diseases.

VR2 polynucleotides or polypeptides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997). The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage. Tissues that may be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis. Additionally, these compounds can be used to treat or prevent cell death (e.g., hematopoletic cell death) during processes of inflammation or tissue injury.

Moreover, VR2 polynucleotides or polypeptides (including VR2 fragments, variants, derivatives, and analogs, and VR2 agonists and antagonists as described herein) may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the VR2 polynucleotides or polypeptides and/or VR2 agonists or antagonists.

Given the activities modulated by VR2, it is readily apparent that a substantially altered (increased or decreased) level of expression of VR2 in an individual compared to the standard or “normal” level produces pathological conditions such as those described above. It will also be appreciated by one of ordinary skill that the VR2 agonists of the invention will exert modulating activities on any of its target cells. Therefore, it will be appreciated that conditions caused by a decrease in the standard or normal level of VR2 mediated activity in an individual, can be treated by administration of VR2 polypeptide or an agonist thereof.

Thus, in one embodiment, the present invention is directed to a method for enhancing (i.e., increasing) VR2 mediated activity (e.g., ion (Ca +2 ) flux) which involves administering to an individual in need of an increased level of VR2 mediated activity, a therapeutically effective amount of VR2 polypeptide, fragment, variant, derivative, or analog, or an agonist capable of increasing VR2 mediated activity. In specific embodiments, VR2 mediated signaling is increased to treat a disease or condition wherein decreased cell survival, secretion, proliferation, migration, and/or differentiation is exhibited.

In another embodiment, the present invention is directed to a method for suppressing (i.e., decreasing) VR2 mediated activity (e.g., ion (Ca +2 ) flux), which involves administering to an individual in need of a decreased level of VR2 mediated activity, a therapeutically effective amount of VR2 polypeptide, fragment, variant, derivative, or analog or an antagonist capable of decreasing VR2 mediated activity. In specific embodiments, VR2 mediated signaling is decreased to treat a disease or condition wherein increased cell survival, secretion, proliferation, migration and/or differentiation is exhibited.

In addition to treating diseases associated with elevated or decreased levels of VR2 mediated activity, the invention encompasses methods of administering VR2 agonists or antagonists to elevate or reduce VR2 mediated biological activity, respectively.

For example, any method which elevates VR2 concentration and/or activity can be used to stimulate hematopoiesis. Using these methods, the VR2 polypeptide and nucleotide sequences and VR2 agonists as described herein may be used to stimulate hematopoiesis. In a specific embodiment, VR2 polypeptides and polynucleotides and/or VR2 agonists are used in erythropoietin therapy, which is directed toward supplementing the oxygen carrying capacity of blood. VR2 treatment within the scope of the invention includes, but is not limited, to patients generally requiring blood transfusions, such as, for example, trauma victims, surgical patients, dialysis patients, and patients with a variety of blood composition-affecting disorders, such as hemophilia, cystic fibrosis, pregnancy, menstrual disorders, early anemia of prematurity, spinal cord injury, space flight, aging, various neoplastic disease states, and the like. Examples of patient conditions that require supplementation of the oxygen carrying capacity of blood and which are within the scope of this invention, include but are not limited to: treatment of blood disorders characterized by low or defective red blood cell production, anemia associated with chronic renal failure, stimulation of reticulocyte response, development of ferrokinetic effects (such as plasma iron turnover effects and marrow transit time effects), erythrocyte mass changes, stimulation of hemoglobin C synthesis, and increasing levels of hematocrit in vertebrates. The invention also provides for treatment to enhance the oxygen-carrying capacity of an individual, such as for example, an individual encountering hypoxic environmental conditions,

The invention also encompasses combining the VR2 polypeptides and polynucleotides and/or VR2 agonists described herein with other proposed or conventional hematopoietic therapies. Thus, for example, VR2 agonists can be combined with compounds that singly exhibit erythropoietic stimulatory effects, such as erythropoietin, testosterone, progenitor cell stimulators, insulin-like growth factor, prostaglandins, serotonin, cyclic AMP, prolactin, and triiodothyzonine. Also encompassed are combinations with compounds generally used to treat aplastic anemia, such as methenolene, stanozolol, and nandrolone; to treat iron-deficiency anemia, such as iron preparations; to treat malignant anemia, such as vitamin B12 and/or folic acid; and to treat hemolytic anemia, such as adrenocortical steroids, e.g., corticoids. See e.g., Resegotti et al., Panminerva Medica 23:243-248 (1981); Kurtz, FEBS Letters 14a: 105-108 (1982); McGonigle et al., Kidney Int . 25:437-444 (1984); and Pavlovic-Kantera, Expt. Hematol ., 8(supp. 8):283-291 (1980).

Compounds that enhance the effects of or synergize with erythropoietin are also useful as adjuvants herein, and include but are not limited to, adrenergic agonists, thyroid hormones, androgens, hepatic erythropoietic factors, erythrotropins, and erythrogenins, See for e.g., Dunn, “Current Concepts in Erythropoiesis”, John Wiley and Sons (Chichester, England, 1983); Weiland et al., Blut . 44:173-175 (1982); Kalmani, Kidney int . 22:383-391 (1982); Shahidi, New Eng. J. Med . 289:72-80 (1973); Urabe et al., J. Exp. Med . 149:1314-1325 (1979); Billat et al., Expt. Hematol . 10:133-140 (1982); Naughton et al., Acta Haemat 69:171-179 (1983); Cognote et al. in abstract 364, Proceedings 7th Intl. Cong. of Endocrinology (Quebec City, Quebec, July 1-7, 1984); and Rothman et al., J. Surg. Oncol . 20:105-108 (1982).

Methods for stimulating hematopoiesis comprise administering a hematopoietically effective amount (i.e, an amount which effects the formation of blood cells) of a pharmaceutical composition containing VR2 or a VR2 agonist to a patient. The VR2 or VR2 agonist is administered to the patient by any suitable technique, including but not limited to, parenteral, sublingual, topical, intrapulmonary and intranasal, and those techniques further discussed herein. The pharmaceutical composition optionally contains one or more members of the group consisting of erythropoietin, testosterone, progenitor cell stimulators, insulin-like growth factor, prostaglandins, serotonin, cyclic AMP, prolactin, triiodothyzonine, methenolene, stanozolol, and nandrolone, iron preparations, vitamin B12, folic acid and/or adrenocortical steroids. The VR2 or VR2 agonist and cotreatment drug(s) are suitably delivered by separate or by the same administration route, and at the same or at different times, depending, e.g., on dosing, the clinical condition of the patient, etc.

For treating abnormal conditions related to an under-expression of VR2 and its activity, or in which elevated or decreased levels of VR2 are desired, several approaches are available. One approach comprises administering to an individual in need of an increased level of VR2 mediated activity in the body, a therapeutically effective amount of an isolated VR2 polypeptide, fragment, variant, derivative or analog of the invention, or a compound which activates VR2, i.e., an agonist as described above, optionally in combination with a pharmaceutically acceptable carrier. Alternatively, gene therapy may be employed to effect the endogenous production of VR2 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector using techniques known in the art. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996).

Further, treatment can be administered, for example, in the form of gene replacement therapy. Specifically, one or more copies of a VR2 nucleotide sequence of the invention that directs the production of a VR2 gene product exhibiting normal function, may be inserted into the appropriate cells within a patient or animal subject, using vectors which include, but are not limited to, adenovirus, adeno-associated virus, retrovirus and herpesvirus vectors, in addition to other particles that introduce DNA into cells, such as liposomes and gene activated matrices. Because the VR2 gene is expressed in hematopoietic tissue, lymph, bone, peripheral blood leukocytes etc, such gene replacement techniques should be capable of delivering VR2 gene sequence to these cells within patients, or, alternatively, should involve direct administration of such VR2 polynucleotide sequences to the site of the cells in which the VR2 gene sequences are to be expressed. Alternatively, targeted homologous recombination can be utilized to correct the defective endogenous VR2 gene and/or regulatory sequences thereof (e.g., promoter and enhancer sequences), or alternatively, to “turn on” other dormant VR2 activity in the appropriate tissue or cell type.

Additional methods which may be utilized to increase the overall level of VR2 expression and/or VR2 activity include the introduction of appropriate VR2-expressing cells, preferably autologous cells, into a patient at positions and in numbers which are sufficient to ameliorate the symptoms of abnormalities in cell growth regulation, cell signaling, and other VR2 mediated activities. Such cells may be either recombinant or non-recombinant. Among the cells which can be administered to increase the overall level of VR2 gene expression in a patient are normal cells, which express the VR2 gene. Cell-based gene therapy techniques are well known to those skilled in the art, see, e.g., Anderson et al., U.S. Pat. No. 5,399,349; and Mulligan & Wilson, U.S. Pat. No. 5,460,959.

Thus, one embodiment of the invention comprises administering to in individual in need of an increased level of VR2 mediated activity compound that stimulates VR2 mediated activity (agonist), such as for example, an antibody or VR2 fragment, variant, derivative or analog of the invention, along with a pharmaceutically acceptable carrier in an amount effective to enhance (i.e., increase) VR2 mediated activity.

If the activity of VR2 is in excess, several approaches are available to reduce or inhibit VR2 activity using molecules derived from the polypeptide and polynucleotide sequences described above. Accordingly, a further aspect of the invention is related to a method for treating an individual in need of a decreased level of VR2 mediated activity in the body comprising, administering to such an individual a composition comprising a therapeutically effective amount of a VR2 polypeptide, fragment, variant, derivative or analog of the invention which acts as a VR2 antagonist or VR2 antagonist identified using the methods described herein, optionally, in combination with a pharmaceutically acceptable carrier. Preferably, VR2 activity is decreased to treat a disease wherein increased cell survival, secretion, proliferation, migration, and/or differentiation is exhibited. Polypeptides, derivatives, variants and analogs of the invention and other compounds which function as antagonists of VR2 can routinely be identified using the assays described infra and other techniques known in the art. Preferred antagonists for use in the present invention are VR2-specific antibodies.

In another approach, VR2 activity can be reduced or inhibited by decreasing the level of VR2 gene expression. In one embodiment, this is accomplished through the use of antisense sequences, either internally generated or separately administered (see, for example, O'Connor, J. Neurochem . 56:560 (1991) in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988).) Antisense technology can be used to control gene expression through antisense DNA or RNA or through triple-helix formation. Antisense techniques are discussed, for example, in Okano, J. Neurochem . 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. ( 1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA. For example, the 5′ coding portion of a polynucleotide that encodes VR2 polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the VR2 polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into polypeptide.

In one embodiment, the VR2 antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the VR2 antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others know in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding VR2, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, Nature 29:304-310 (1981), the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A . 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., Nature 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a VR2 gene. However, absolute complementarity, although preferred, is not required. A sequence “complementary to at least a portion of an RNA,” referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded VR2 antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a VR2 RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Potential VR2 antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published Oct. 4, 1990; Sarver et al., Science 247:1222-1225 (1990).) While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy VR2 mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5′-UG-3′. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of VR2 ( FIGS. 1A-1D ; SEQ ID NO:1). Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5′ end of the VR2 mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. Since ribozymes, unlike antisense molecules are catalytic, a lower intracellular concentration is required for efficiency.

Endogenous VR2 gene expression can also be reduced by inactivating or “knocking out” the VR2 gene or its promoter using targeted homologous recombination (e.g., see Smithies et al, Nature 317:330-234 (1985); Thomas et al., Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). Such approach can be adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors.

Alternatively, endogenous VR2 gene expression can be reduced by targeted deoxyribonucleotide sequences complementary to the regulatory region of the VR2 gene (i.e., the VR2 promoter and/or enhancers) to form triple helical structures that prevent transcription of the VR2 gene in target cells in the body, (see, generally, Helene et al., Ann, N.Y. Acad. Sci . 660:27-36 (1992); Helene, C., Anticancer Drug Des ., 6(6):569-584 (1991); and Maher, L. J., Bioassays 14(12):807-815 (1992)). Thus, one embodiment of the invention comprises administering to an individual in need of a decreased level of VR2 mediated activity, a VR2 inhibitor compound (antagonist), such as for example, an antibody or VR2 fragment, variant, derivative or analog of the invention, along with a pharmaceutically acceptable carrier in an amount effective to suppress (i.e., lower) VR2 mediated activity.

Formulation and administration

It will be appreciated that conditions caused by a decrease in the standard or normal level of VR2 mediated activity in an individual, can be treated by administration of VR2 polypeptide or fragment, variant, derivative, or analog of the invention or an agonist thereof. Thus, the invention further provides a method of treating an individual in need of an increased level of VR2 mediated activity comprising administering to such an individual a pharmaceutical composition comprising an effective amount of an isolated VR2 polynucleotide or polypeptide; or fragment, variant, derivative, or analog of the invention, such as for example, the full length form of the VR2 encoding polynucleotide, effective to increase the VR2 mediated activity level in such an individual.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. As a general proposition, the total pharmaceutically effective amount of VR2 polypeptide administered parenterally per dose will be in the range of about 1 μμg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans this dose is in the range of 0.1-100 mg/kg of subject, or between about 0.01 and 1 mg/kg/day. If given continuously, the VR2 polypeptide is typically administered at a dose rate of about 1 μg/kg/hour to about 50 μg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Pharmaceutical compositions containing the VR2 polypeptides and polynucleotides of the invention (including fragments, variants, derivatives or analogs), and VR2 agonists and antagonists may be routinely formulated in combination with a pharmaceutically acceptable carrier. By “pharmaceutically acceptable carrier” is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. In a specific embodiment, “pharmaceutically acceptable” means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly humans. Nonlimiting examples of suitable pharmaceutical carriers according to this embodiment are provided in “Remington's Pharmaceutical Sciences” by E. W. Martin, and include sterile liquids, such as water, saline, buffered saline, glycerol, ethanol, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Formulation should suit the mode of administration, and is well within the skill of the art. For example, water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can be employed as liquid carriers, particularly for injectable solutions. The invention additionally relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the present invention may be administered alone or in conjunction with other compounds, such as therapeutic compounds. The pharmaceutical composition of the invention may be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray. Preferred forms of systemic administration of the pharmaceutical compositions include parenteral injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, intrasternal, intraarticular or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as “gene therapy” as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Gene Mapping

The nucleic acid molecules of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

In certain preferred embodiments in this regard, the cDNA herein disclosed is used to clone genomic DNA of a VR2 gene. This can be accomplished using a variety of well known techniques and libraries, which generally are available commercially. The genomic DNA then is used for in situ chromosome mapping using well known techniques for this purpose.

In addition, in some cases, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3′ untranslated region of the gene is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Fluorescence in situ hybridization (“FISH”) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with probes from the cDNA as short as 50 or 60 bp. For a review of this technique, see Verma et al., Human Chromosomes: A Manual Of Basic Techniques , Pergamon Press, New York (1988).

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance In Man , available on-line through Johns Hopkins University, Welch Medical Library. The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting. Thus, the present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

The entire disclosure of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference.

Further, the Sequence Listing submitted herewith in paper and computer readable form is herein incorporated by reference in their entireties.

EXAMPLES

Example 1

Isolation of the VR2 CDNA Clone From the Deposited Sample

The cDNA for VR2 is inserted into the EcoRI and Xho I multiple cloning site of UniZAP XR (Stratagene). UniZAP XR contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59- (1993)).

Two approaches can be used to isolate VR2 from the deposited sample. First, a specific polynucleotide of SEQ ID NO:1 with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with 32 P-g-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Press, Cold Spring, N.Y. (1982)). The plasmid mixture is transformed into a suitable host (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual , 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:1 (i.e., within the region of SEQ ID NO:1 bounded by the 5′ NT and the 3′ NT of the clone) are synthesized and used to amplify the VR2 cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl 2 , 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5′ or 3′ non-coding portions of the VR2 gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5′ and 3′ “RACE” protocols which are well known in the art. For instance, a method similar to 5′ RACE is available for generating the missing 5′ end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res . 21(7):1683-1684 (1993)).

Briefly, a specific RNA oligonucleotide is ligated to the 5′ ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the VR2 gene of interest is used to PCR amplify the 5′ portion of the VR2 full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5′ phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5′ ends of messenger RNAs. This reaction leaves a 5′ phosphate group at the 5′ end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5′ end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5′ end sequence belongs to the VR2 gene.

Example 2

Isolation of VR2 Genomic Clones

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:1., according to the method described in Example 1. (See also, Sambrook.)

Example 3

Chromosomal Mapping of VR2

An oligonucleotide primer set is designed according to the sequence at the 5′ end of SEQ ID NO:1. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5% agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 4

Bacterial Expression of VR2

VR2 polynucleotide encoding a VR2 polypeptide of the invention is amplified using PCR oligonucleotide primers corresponding to the 5′ and 3′ ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5′ end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, Calif.). This plasmid vector encodes antibiotic resistance (Amp r , a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

Specifically, to clone the full-length VR2 polypeptide in a bacterial vector, the 5′ primer has the sequence 5′ GCAGCA CATATG GTCAGTCTC TGGTGGCTAGCCTGTCCTGACAG 3′ (SEQ ID NO:4) containing the underlined NdeI restriction site followed by a number of nucleotides of the amino terminal coding sequence of the full-length VR2 sequence in SEQ ID NO:1. One of ordinary skill in the art would appreciate, of course, that the point in the protein coding sequence where the 5′ primer begins may be varied to amplify a DNA segment encoding any desired portion of the complete VR2 protein shorter or longer than the full-length form of the protein. The 3′ primer has the sequence 5′GCAGCA GGTACCT CAGTTGGACTGGAGGAGCTGGACGGGCACATAG 3′ (SEQ ID NO:5) containing the underlined Asp718 restriction site followed by a number nucleotides complementary to the 3′ end of the coding sequence of the VR2 DNA sequence of SEQ ID NO:1.

The pQE-9 vector is digested with NdeI and Asp718 and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan r ). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D. 600 ) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000×g).

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a VR2 polynucleotide, called pHE4a. (ATCC Accession Number 209645, deposited Feb. 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, Md.). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and KpnI, BamHII, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5′ primer) and XbaI, BamHI, XhoI, or Asp718 (3′ primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 5

Cloning and Expression of VR2 in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert VR2 polynucleotide into a baculovirus to express VR2. This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, XbaI and Asp718. The polyadenylation site of the simian virus 40 (“SV40”) is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned VR2 polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the VR2 cDNA sequence contained in the deposited clone, including the AUG initiation codon and any naturally associated leader sequence, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., “A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures,” Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

More specifically, the cDNA sequence encoding the full length VR2 protein in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence shown in SEQ ID NO:1, is amplified using PCR oligonucleotide primers corresponding to the 5′ and 3′ sequences of the gene. The 5′ primer has the sequence 5 ′ GCA GCA AGATCT GCC ATC ATG GTC AGT CTC TGG TGG CTA GCC TGT CCT GAC AG 3 ′ (SEQ ID NO:6) containing the BglII restriction enzyme site, an efficient signal for initiation of translation in eukaryotic cells (Kozak, M., J. Mol. Biol . 196:947-950 (1987)), followed by a number of nucleotides of the sequence of the complete VR2 protein shown in FIGS. 1A-1D , beginning with the AUG initiation codon. The 3′ primer has the sequence 5′ GCA GCA TCTAGA T CAG TTG GAC TGG AGG AGC TGG ACG GGC ACA TAG 3′ (SEQ ID NO:7) containing the XbaI restriction site followed by a number of nucleotides complementary to the 3 ′noncoding sequence in FIGS. 1A-1D .

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit (“Geneclean,” BIO 101 Inc., La Jolla, Calif.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit (“Geneclean” BIO 101 Inc., La Jolla, Calif.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. E. coli HB 101 or other suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, Calif.) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA (“BaculoGold™ baculovirus DNA”, Pharmingen, San Diego, Calif.), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, Md.). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Graces medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, supra. An agarose gel with “Blue Gal” (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a “plaque assay” of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection (“MOI”) of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, Md.). After 42 hours, 5 uCi of 35 S-methionine and 5 uCi 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced VR2 polypeptide.

Example 6

Expression of VR2 in Mammalian Cells

VR2 polypeptide can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2DHFR (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, VR2 polypeptide can be expressed in stable cell lines containing the VR2 polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected VR2 gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., e al., J. Biol. Chem . 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991)). Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J . 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-DHFR (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology , 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985)). Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of VR2. The vectors also contain the 3′ intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC4 is digested with BamHI and XbaI and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

The cDNA sequence encoding the full length VR2 protein in the deposited clone is amplified using PCR oligonucleotide primers corresponding to the 5′ and 3′ sequences of the gene. The 5′ primer has the sequence 5 ′ GCA GCA AGATCT GCC ATC ATG GTC AGT CTC TGG TGG CTA GCC TGT CCT GAC AG 3′ (SEQ ID NO:6) containing the BglII restriction enzyme site, an efficient signal for initiation of translation in eukaryotic cells (Kozak, M., J. Mol. Biol . 196:947-950 (1987)), followed by a number of nucleotides of the sequence of the complete VR2 protein shown in FIGS. 1A-1D , beginning with the AUG initiation codon. The 3′ primer has the sequence 5′ GCA GCA TCTAGA TCA GTT GGA CTG GAG GAG CTG GAC GGG CAC ATAG 3′ (SEQ ID NO:7) containing the XbaI restriction site followed by a number of nucleotides complementary to the 3′ noncoding sequence in FIGS. 1A-1D .

If a naturally occurring signal sequence is used to produce a secreted protein, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence in an effort to secrete the protein from the cell. (See, e.g., WO 96/34891.)

The amplified fragment is then digested with the BglII and XbaI and purified on a 1% agarose gel using a commercially available kit (“Geneclean,” BIO 101 Inc., La Jolla, Calif.). The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC4 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μg of the expression plasmid pC4 is cotransfected with 0.5 ug of the plasmid pSVneo using lipofectin (Felgner et al., supra). The plasmid pSV2-neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 uM, 2 uM, 5 uM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100-200 uM. Expression of VR2 is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 7

Construction of N-Terminal and/or C-Terminal Deletion Mutants

The following general approach may be used to clone a N-terminal or C-terminal deletion VR2 deletion mutant. Generally, two oligonucleotide primers of about 15-25 nucleotides are derived from the desired 5′ and 3′ positions of a polynucleotide of SEQ ID NO:1. The 5′ and 3′ positions of the primers are determined based on the desired VR2 polynucleotide fragment. An initiation and stop codon are added to the 5′ and 3′ primers respectively, if necessary, to express the VR2 polypeptide fragment encoded by the polynucleotide fragment. Preferred VR2 polynucleotide fragments are those encoding the N-terminal and C-terminal deletion mutants disclosed above in the “Polynucleotide and Polypeptide Fragments” section of the Specification.

Additional nucleotides containing restriction sites to facilitate cloning of the VR2 polynucleotide fragment in a desired vector may also be added to the 5′ and 3′ primer sequences. The VR2 polynucleotide fragment is amplified from genomic DNA or from the deposited cDNA clone using the appropriate PCR oligonucleotide primers and conditions discussed herein or known in the art. The VR2 polypeptide fragments encoded by the VR2 polynucleotide fragments of the present invention may be expressed and purified in the same general manner as the full length polypeptides, although routine modifications may be necessary due to the differences in chemical and physical properties between a particular fragment and full length polypeptide.

As a means of exemplifying but not limiting the present invention, the polynucleotide encoding the VR2 polypeptide fragment L-39 to N-889 is amplified and cloned as follows: A 5′ primer is generated comprising a restriction enzyme site followed by an initiation codon in frame with the polynucleotide sequence encoding the N-terminal portion of the polypeptide fragment beginning with L-39. A complementary 3′ primer is generated comprising a restriction enzyme site followed by a stop codon in frame with the polynucleotide sequence encoding C-terminal portion of the VR2 polypeptide fragment ending with N-889.

The amplified polynucleotide fragment and the expression vector are digested with restriction enzymes which recognize the sites in the primers. The digested polynucleotides are then ligated together. The VR2 polynucleotide fragment is inserted into the restricted expression vector, preferably in a manner which places the VR2 polypeptide fragment coding region downstream from the promoter. The ligation mixture is transformed into competent E. coli cells using standard procedures and as described in the Examples herein. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

Example 8

Protein Fusions of VR2

VR2 polypeptides are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of VR2 polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988)). Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to VR2 polypeptides can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5′ and 3′ ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3′ BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and VR2 polynucleotide, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.) Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACC GTGCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCC CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGT CACATGCGTGGTGGTGGACGTAAGCCACGAAGACCCTGAGGTCAAG TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAA AGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGT CCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG TGCAAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCA TCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCT GCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACC TGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGT GCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGG ACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT GCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTG TCTCCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:8)

Example 9

Production of an Antibody

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing VR2 is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of VR2 protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol . 6:511 (1976); Köhler et al., Eur. J. Immunol . 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T - Cell Hybridomas , Elsevier, N.Y., pp. 563-681 (1981)). In general, such procedures involve immunizing an animal (preferably a mouse) with VR2 polypeptide or, more preferably, with a secreted VR2 polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degree C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al., Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the VR2 polypeptide.

Alternatively, additional antibodies capable of binding to VR2 polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the VR2 specific antibody can be blocked by VR2 Such antibodies comprise anti-idiotypic antibodies to the VR2 specific antibody and can be used to immunize an animal to induce formation of further VR2 specific antibodies.

It will be appreciated that Fab and F(ab′)2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′)2 fragments). Alternatively, secreted VR2 protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use “humanized” chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202(1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Pat. No. 4,816,567; Taniguchi et al. EP 171496; Morrison et al., EP 173494, Neuberger et al, WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985)).

Example 10

Method of Detecting Abnormal Levels of VR2 in a Biological Sample

VR2 polypeptides can be detected in a biological sample, and if an increased or decreased level of VR2 is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect VR2 in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies to VR2 at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 11. The wells are blocked so that non-specific binding of VR2 to the well is reduced.

The coated wells are then incubated for >2 hours at RT with a sample containing VR2. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded VR2.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate I hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot VR2 polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the VR2 in the sample using the standard curve.

Example 11

Formulating a Polypeptide

The VR2 composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the VR2 polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The “effective amount” for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of VR2 administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, VR2 is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing VR2 are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. “Pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term “parenteral” as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

VR2 is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U., et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer, R., et al., J. Biomed. Mater. Res . 15:167-277 (1981), and Langer, R., Chem. Tech . 12:98-105 (1982)), ethylene vinyl acetate (Langer, R., et al.) or poly-D-(−)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped VR2 polypeptides. Liposomes containing the VR2 are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, VR2 is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting VR2 uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

VR2 is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

VR2 used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

VR2 polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous VR2 polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized VR2 polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, VR2 may be employed in conjunction with other therapeutic compounds.

Example 12

Method of Treatment Using Gene Therapy—in vivo

Another aspect of the present invention is using in vivo gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) VR2 sequences into an animal to increase or decrease the expression of the VR2 polypeptide. The VR2 polynucleotide may be operatively linked to a promoter or any other genetic elements necessary for the expression of the VR2 polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Pat. Nos. 5,693,622, 5,705,151, 5,580,859; Tabata H., et al., Cardiovasc. Res . 35(3):470-479 (1997), Chao, J., et al., Pharmacol. Res . 35(6):517-522 (1997), Wolff, J. A., Neuromuscul. Disord . 7(5):314-318 (1997), Schwartz, B., et al., Gene Ther . 3(5):405-411 (1996), Tsurumi, Y., et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The VR2 polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The VR2 polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term “naked” polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the VR2 polynucleotides may also be delivered in liposome formulations (such as those taught in Felgner, P. L., et al., Ann. NY Acad. Sci . 772:126-139 (1995) and Abdallah, B., et at, Biol. Cell 85(1):1-7) (1995) which can be prepared by methods well known to those skilled in the art.

The VR2 polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The VR2 polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked VR2 polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked VR2 polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected VR2 polynucleotide in muscle in vivo is determined as follows. Suitable VR2 template DNA for production of mRNA coding for VR2 polypeptide is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The VR2 template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for VR2 protein expression. A time course for VR2 protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of VR2 DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using VR2 naked DNA.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference.

Moreover, the sequence submitted herewith in paper and computer readable form are herein incorporated by reference in their entireties.

67 1 2805 DNA Homo sapiens CDS (5)..(2674) 1gcag atg gtc agt ctc tgg tgg cta gcc tgt cct gac agg gga gag tta 49 Met Val Ser Leu Trp Trp Leu Ala Cys Pro Asp Arg Gly Glu Leu 1 5 10 15agc tcc cgt tct cca ccg tgc cgg ctg gcc agg tgg gct gag ggt gac 97Ser Ser Arg Ser Pro Pro Cys Arg Leu Ala Arg Trp Ala Glu Gly Asp 20 25 30cga gag acc aga acc tgc ttg ctg gag ctt agt gct cag agc tgg gga 145Arg Glu Thr Arg Thr Cys Leu Leu Glu Leu Ser Ala Gln Ser Trp Gly 35 40 45ggg agg ttc cgc cgc tcc tct gct gtc agc acc ggc agc ccc tcc cgg 193Gly Arg Phe Arg Arg Ser Ser Ala Val Ser Thr Gly Ser Pro Ser Arg 50 55 60ctt cac ttc ctc ccg cag ccc ctg cta ctg aga agc tcc ggg atc cca 241Leu His Phe Leu Pro Gln Pro Leu Leu Leu Arg Ser Ser Gly Ile Pro 65 70 75gca gcc gcc acg ccc tgg cct cag cct gcg ggg ctc cag tca ggc caa 289Ala Ala Ala Thr Pro Trp Pro Gln Pro Ala Gly Leu Gln Ser Gly Gln 80 85 90 95cac cga cgc gca cgt ggg agg aag aca gga ccc ttg aca tct cca tct 337His Arg Arg Ala Arg Gly Arg Lys Thr Gly Pro Leu Thr Ser Pro Ser 100 105 110gca cag agg tcc tgg ctg gac cga gct atg cct cct cct cct agg atg 385Ala Gln Arg Ser Trp Leu Asp Arg Ala Met Pro Pro Pro Pro Arg Met 115 120 125acc tca ccc tcc agc tct cca gtt ttc agg ttg gag aca tta gat gga 433Thr Ser Pro Ser Ser Ser Pro Val Phe Arg Leu Glu Thr Leu Asp Gly 130 135 140ggc caa gaa gat ggc tct gag gcg gac aga gga aag ctg gat ttt ggg 481Gly Gln Glu Asp Gly Ser Glu Ala Asp Arg Gly Lys Leu Asp Phe Gly 145 150 155agc ggg ctg cct ccc atg gag tca cag ttc cag ggc gag gac cgg aaa 529Ser Gly Leu Pro Pro Met Glu Ser Gln Phe Gln Gly Glu Asp Arg Lys160 165 170 175ttc gcc cct cag ata aga gtc aac ctc aac tac cga aag gga aca ggt 577Phe Ala Pro Gln Ile Arg Val Asn Leu Asn Tyr Arg Lys Gly Thr Gly 180 185 190gcc agt cag ccg gat cca aac cga ttt gac cga gat cgg ctc ttc aat 625Ala Ser Gln Pro Asp Pro Asn Arg Phe Asp Arg Asp Arg Leu Phe Asn 195 200 205gcg gtc tcc cgg ggt gtc ccc gag gat ctg gct gga ctt cca gag tac 673Ala Val Ser Arg Gly Val Pro Glu Asp Leu Ala Gly Leu Pro Glu Tyr 210 215 220ctg agc aag acc agc aag tac ctc acc gac tcg gaa tac aca gag ggc 721Leu Ser Lys Thr Ser Lys Tyr Leu Thr Asp Ser Glu Tyr Thr Glu Gly 225 230 235tcc aca ggt aag acg tgc ctg atg aag gct gtg ctg aac ctt aag gac 769Ser Thr Gly Lys Thr Cys Leu Met Lys Ala Val Leu Asn Leu Lys Asp240 245 250 255ggg gtc aat gcc tgc att ctg cca ctg ctg cag atc gac cgg gac tct 817Gly Val Asn Ala Cys Ile Leu Pro Leu Leu Gln Ile Asp Arg Asp Ser 260 265 270ggc aat cct cag ccc ctg gta aat gcc cag tgc aca gat gac tat tac 865Gly Asn Pro Gln Pro Leu Val Asn Ala Gln Cys Thr Asp Asp Tyr Tyr 275 280 285cga ggc cac agc gct ctg cac atc gcc att gag aag agg agt ctg cag 913Arg Gly His Ser Ala Leu His Ile Ala Ile Glu Lys Arg Ser Leu Gln 290 295 300tgt gtg aag ctc ctg gtg gag aat ggg gcc aat gtg cat gcc cgg gcc 961Cys Val Lys Leu Leu Val Glu Asn Gly Ala Asn Val His Ala Arg Ala 305 310 315tgc ggc cgc ttc ttc cag aag ggc caa ggg act tgc ttt tat ttc ggt 1009Cys Gly Arg Phe Phe Gln Lys Gly Gln Gly Thr Cys Phe Tyr Phe Gly320 325 330 335gag cta ccc ctc tct ttg gcc gct tgc acc aag cag tgg gat gtg gta 1057Glu Leu Pro Leu Ser Leu Ala Ala Cys Thr Lys Gln Trp Asp Val Val 340 345 350agc tac ctc ctg gag aac cca cac cag ccc gcc agc ctg cag gcc act 1105Ser Tyr Leu Leu Glu Asn Pro His Gln Pro Ala Ser Leu Gln Ala Thr 355 360 365gac tcc cag ggc aac aca gtc ctg cat gcc cta gtg atg atc tcg gac 1153Asp Ser Gln Gly Asn Thr Val Leu His Ala Leu Val Met Ile Ser Asp 370 375 380aac tca gct gag aac att gca ctg gtg acc agc atg tat gat ggg ctc 1201Asn Ser Ala Glu Asn Ile Ala Leu Val Thr Ser Met Tyr Asp Gly Leu 385 390 395ctc caa gct ggg gcc cgc ctc tgc cct acc gtg cag ctt gag gac atc 1249Leu Gln Ala Gly Ala Arg Leu Cys Pro Thr Val Gln Leu Glu Asp Ile400 405 410 415cgc aac ctg cag gat ctc acg cct ctg aag ctg gcc gcc aag gag ggc 1297Arg Asn Leu Gln Asp Leu Thr Pro Leu Lys Leu Ala Ala Lys Glu Gly 420 425 430aag atc gag att ttc agg cac atc ctg cag cgg gag ttt tca gga ctg 1345Lys Ile Glu Ile Phe Arg His Ile Leu Gln Arg Glu Phe Ser Gly Leu 435 440 445agc cac ctt tcc cga aag ttc acc gag tgg tgc tat ggg cct gtc cgg 1393Ser His Leu Ser Arg Lys Phe Thr Glu Trp Cys Tyr Gly Pro Val Arg 450 455 460gtg tcg ctg tat gac ctg gct tct gtg gac agc tgt gag gag aac tca 1441Val Ser Leu Tyr Asp Leu Ala Ser Val Asp Ser Cys Glu Glu Asn Ser 465 470 475gtg ctg gag atc att gcc ttt cat tgc aag agc ccg cac cga cac cga 1489Val Leu Glu Ile Ile Ala Phe His Cys Lys Ser Pro His Arg His Arg480 485 490 495atg gtc gtt ttg gag ccc ctg aac aaa ctg ctg cag gcg aaa tgg gat 1537Met Val Val Leu Glu Pro Leu Asn Lys Leu Leu Gln Ala Lys Trp Asp 500 505 510ctg ctc atc ccc aag ttc ttc tta aac ttc ctg tgt aat ctg atc tac 1585Leu Leu Ile Pro Lys Phe Phe Leu Asn Phe Leu Cys Asn Leu Ile Tyr 515 520 525atg ttc atc ttc acc gct gtt gcc tac cat cag cct acc ctg aag aag 1633Met Phe Ile Phe Thr Ala Val Ala Tyr His Gln Pro Thr Leu Lys Lys 530 535 540gcc gcc cct cac ctg aaa gcg gag gtt gga aac tcc atg ctg ctg acg 1681Ala Ala Pro His Leu Lys Ala Glu Val Gly Asn Ser Met Leu Leu Thr 545 550 555ggc cac atc ctt atc ctg cta ggg ggg atc tac ctc ctc gtg ggc cag 1729Gly His Ile Leu Ile Leu Leu Gly Gly Ile Tyr Leu Leu Val Gly Gln560 565 570 575ctg tgg tac ttc tgg cgg cgc cac gtg ttc atc tgg atc tcg ttc ata 1777Leu Trp Tyr Phe Trp Arg Arg His Val Phe Ile Trp Ile Ser Phe Ile 580 585 590gac agc tac ttt gaa atc ctc ttc ctg ttc cag gcc ctg ctc aca gtg 1825Asp Ser Tyr Phe Glu Ile Leu Phe Leu Phe Gln Ala Leu Leu Thr Val 595 600 605gtg tcc cag gtg ctg tgt ttc ctg gcc atc gag tgg tac ctg ccc ctg 1873Val Ser Gln Val Leu Cys Phe Leu Ala Ile Glu Trp Tyr Leu Pro Leu 610 615 620ctt gtg tct gcg ctg gtg ctg ggc tgg ctg aac ctg ctt tac tat aca 1921Leu Val Ser Ala Leu Val Leu Gly Trp Leu Asn Leu Leu Tyr Tyr Thr 625 630 635cgt ggc ttc cag cac aca ggc atc tac agt gtc atg atc cag aag gtc 1969Arg Gly Phe Gln His Thr Gly Ile Tyr Ser Val Met Ile Gln Lys Val640 645 650 655atc ctg cgg gac ctg ctg cgc ttc ctt ctg atc tac tta gtc ttc ctt 2017Ile Leu Arg Asp Leu Leu Arg Phe Leu Leu Ile Tyr Leu Val Phe Leu 660 665 670ttc ggc ttc gct gta gcc ctg gtg agc ctg agc cag gag gct tgg cgc 2065Phe Gly Phe Ala Val Ala Leu Val Ser Leu Ser Gln Glu Ala Trp Arg 675 680 685ccc gaa gct cct aca ggc ccc aat gcc aca gag tca gtg cag ccc atg 2113Pro Glu Ala Pro Thr Gly Pro Asn Ala Thr Glu Ser Val Gln Pro Met 690 695 700gag gga cag gag gac gag ggc aac ggg gcc cag tac agg ggt atc ctg 2161Glu Gly Gln Glu Asp Glu Gly Asn Gly Ala Gln Tyr Arg Gly Ile Leu 705 710 715gaa gcc tcc ttg gag ctc ttc aaa ttc acc atc ggc atg ggc gag ctg 2209Glu Ala Ser Leu Glu Leu Phe Lys Phe Thr Ile Gly Met Gly Glu Leu720 725 730 735gcc ttc cag gag cag ctg cac ttc cgc ggc atg gtg ctg ctg ctg ctg 2257Ala Phe Gln Glu Gln Leu His Phe Arg Gly Met Val Leu Leu Leu Leu 740 745 750ctg gcc tac gtg ctg ctc acc tac atc ctg ctg ctc aac atg ctc atc 2305Leu Ala Tyr Val Leu Leu Thr Tyr Ile Leu Leu Leu Asn Met Leu Ile 755 760 765gcc ctc atg agc gag acc gtc aac agt gtc gcc act gac agc tgg agc 2353Ala Leu Met Ser Glu Thr Val Asn Ser Val Ala Thr Asp Ser Trp Ser 770 775 780atc tgg aag ctg cag aaa gcc atc tct gtc ctg gag atg gag aat ggc 2401Ile Trp Lys Leu Gln Lys Ala Ile Ser Val Leu Glu Met Glu Asn Gly 785 790 795tat tgg tgg tgc agg aag aag cag cgg gca ggt gtg atg ctg acc gtt 2449Tyr Trp Trp Cys Arg Lys Lys Gln Arg Ala Gly Val Met Leu Thr Val800 805 810 815ggc act aag cca gat ggc agc ccc gat gag cgc tgg tgc ttc agg gtg 2497Gly Thr Lys Pro Asp Gly Ser Pro Asp Glu Arg Trp Cys Phe Arg Val 820 825 830gag gag gtg aac tgg gct tca tgg gag cag acg ctg cct acg ctg tgt 2545Glu Glu Val Asn Trp Ala Ser Trp Glu Gln Thr Leu Pro Thr Leu Cys 835 840 845gag gac ccg tca ggg gca ggt gtc cct cga act ctc gag aac cct gtc 2593Glu Asp Pro Ser Gly Ala Gly Val Pro Arg Thr Leu Glu Asn Pro Val 850 855 860ctg gct tcc cct ccc aag gag gat gag gat ggt gcc tct gag gaa aac 2641Leu Ala Ser Pro Pro Lys Glu Asp Glu Asp Gly Ala Ser Glu Glu Asn 865 870 875tat gtg ccc gtc cag ctc ctc cag tcc aac tga tggcccagat gcagcaggag 2694Tyr Val Pro Val Gln Leu Leu Gln Ser Asn880 885 890gccagaggac agagcagagg atctttccaa ccacatctgc tggctctggg gtcccagtga 2754attctggtgg caaatatata ttttcactaa ctcaaaaaaa aaaaaaaaaa a 2805 2 889 PRT Homo sapiens 2Met Val Ser Leu Trp Trp Leu Ala Cys Pro Asp Arg Gly Glu Leu Ser 1 5 10 15Ser Arg Ser Pro Pro Cys Arg Leu Ala Arg Trp Ala Glu Gly Asp Arg 20 25 30Glu Thr Arg Thr Cys Leu Leu Glu Leu Ser Ala Gln Ser Trp Gly Gly 35 40 45Arg Phe Arg Arg Ser Ser Ala Val Ser Thr Gly Ser Pro Ser Arg Leu 50 55 60His Phe Leu Pro Gln Pro Leu Leu Leu Arg Ser Ser Gly Ile Pro Ala 65 70 75 80Ala Ala Thr Pro Trp Pro Gln Pro Ala Gly Leu Gln Ser Gly Gln His 85 90 95Arg Arg Ala Arg Gly Arg Lys Thr Gly Pro Leu Thr Ser Pro Ser Ala 100 105 110Gln Arg Ser Trp Leu Asp Arg Ala Met Pro Pro Pro Pro Arg Met Thr 115 120 125Ser Pro Ser Ser Ser Pro Val Phe Arg Leu Glu Thr Leu Asp Gly Gly 130 135 140Gln Glu Asp Gly Ser Glu Ala Asp Arg Gly Lys Leu Asp Phe Gly Ser145 150 155 160Gly Leu Pro Pro Met Glu Ser Gln Phe Gln Gly Glu Asp Arg Lys Phe 165 170 175Ala Pro Gln Ile Arg Val Asn Leu Asn Tyr Arg Lys Gly Thr Gly Ala 180 185 190Ser Gln Pro Asp Pro Asn Arg Phe Asp Arg Asp Arg Leu Phe Asn Ala 195 200 205Val Ser Arg Gly Val Pro Glu Asp Leu Ala Gly Leu Pro Glu Tyr Leu 210 215 220Ser Lys Thr Ser Lys Tyr Leu Thr Asp Ser Glu Tyr Thr Glu Gly Ser225 230 235 240Thr Gly Lys Thr Cys Leu Met Lys Ala Val Leu Asn Leu Lys Asp Gly 245 250 255Val Asn Ala Cys Ile Leu Pro Leu Leu Gln Ile Asp Arg Asp Ser Gly 260 265 270Asn Pro Gln Pro Leu Val Asn Ala Gln Cys Thr Asp Asp Tyr Tyr Arg 275 280 285Gly His Ser Ala Leu His Ile Ala Ile Glu Lys Arg Ser Leu Gln Cys 290 295 300Val Lys Leu Leu Val Glu Asn Gly Ala Asn Val His Ala Arg Ala Cys305 310 315 320Gly Arg Phe Phe Gln Lys Gly Gln Gly Thr Cys Phe Tyr Phe Gly Glu 325 330 335Leu Pro Leu Ser Leu Ala Ala Cys Thr Lys Gln Trp Asp Val Val Ser 340 345 350Tyr Leu Leu Glu Asn Pro His Gln Pro Ala Ser Leu Gln Ala Thr Asp 355 360 365Ser Gln Gly Asn Thr Val Leu His Ala Leu Val Met Ile Ser Asp Asn 370 375 380Ser Ala Glu Asn Ile Ala Leu Val Thr Ser Met Tyr Asp Gly Leu Leu385 390 395 400Gln Ala Gly Ala Arg Leu Cys Pro Thr Val Gln Leu Glu Asp Ile Arg 405 410 415Asn Leu Gln Asp Leu Thr Pro Leu Lys Leu Ala Ala Lys Glu Gly Lys 420 425 430Ile Glu Ile Phe Arg His Ile Leu Gln Arg Glu Phe Ser Gly Leu Ser 435 440 445His Leu Ser Arg Lys Phe Thr Glu Trp Cys Tyr Gly Pro Val Arg Val 450 455 460Ser Leu Tyr Asp Leu Ala Ser Val Asp Ser Cys Glu Glu Asn Ser Val465 470 475 480Leu Glu Ile Ile Ala Phe His Cys Lys Ser Pro His Arg His Arg Met 485 490 495Val Val Leu Glu Pro Leu Asn Lys Leu Leu Gln Ala Lys Trp Asp Leu 500 505 510Leu Ile Pro Lys Phe Phe Leu Asn Phe Leu Cys Asn Leu Ile Tyr Met 515 520 525Phe Ile Phe Thr Ala Val Ala Tyr His Gln Pro Thr Leu Lys Lys Ala 530 535 540Ala Pro His Leu Lys Ala Glu Val Gly Asn Ser Met Leu Leu Thr Gly545 550 555 560His Ile Leu Ile Leu Leu Gly Gly Ile Tyr Leu Leu Val Gly Gln Leu 565 570 575Trp Tyr Phe Trp Arg Arg His Val Phe Ile Trp Ile Ser Phe Ile Asp 580 585 590Ser Tyr Phe Glu Ile Leu Phe Leu Phe Gln Ala Leu Leu Thr Val Val 595 600 605Ser Gln Val Leu Cys Phe Leu Ala Ile Glu Trp Tyr Leu Pro Leu Leu 610 615 620Val Ser Ala Leu Val Leu Gly Trp Leu Asn Leu Leu Tyr Tyr Thr Arg625 630 635 640Gly Phe Gln His Thr Gly Ile Tyr Ser Val Met Ile Gln Lys Val Ile 645 650 655Leu Arg Asp Leu Leu Arg Phe Leu Leu Ile Tyr Leu Val Phe Leu Phe 660 665 670Gly Phe Ala Val Ala Leu Val Ser Leu Ser Gln Glu Ala Trp Arg Pro 675 680 685Glu Ala Pro Thr Gly Pro Asn Ala Thr Glu Ser Val Gln Pro Met Glu 690 695 700Gly Gln Glu Asp Glu Gly Asn Gly Ala Gln Tyr Arg Gly Ile Leu Glu705 710 715 720Ala Ser Leu Glu Leu Phe Lys Phe Thr Ile Gly Met Gly Glu Leu Ala 725 730 735Phe Gln Glu Gln Leu His Phe Arg Gly Met Val Leu Leu Leu Leu Leu 740 745 750Ala Tyr Val Leu Leu Thr Tyr Ile Leu Leu Leu Asn Met Leu Ile Ala 755 760 765Leu Met Ser Glu Thr Val Asn Ser Val Ala Thr Asp Ser Trp Ser Ile 770 775 780Trp Lys Leu Gln Lys Ala Ile Ser Val Leu Glu Met Glu Asn Gly Tyr785 790 795 800Trp Trp Cys Arg Lys Lys Gln Arg Ala Gly Val Met Leu Thr Val Gly 805 810 815Thr Lys Pro Asp Gly Ser Pro Asp Glu Arg Trp Cys Phe Arg Val Glu 820 825 830Glu Val Asn Trp Ala Ser Trp Glu Gln Thr Leu Pro Thr Leu Cys Glu 835 840 845Asp Pro Ser Gly Ala Gly Val Pro Arg Thr Leu Glu Asn Pro Val Leu 850 855 860Ala Ser Pro Pro Lys Glu Asp Glu Asp Gly Ala Ser Glu Glu Asn Tyr865 870 875 880Val Pro Val Gln Leu Leu Gln Ser Asn 885 3 838 PRT Rattus norvegicus 3Met Glu Gln Arg Ala Ser Leu Asp Ser Glu Glu Ser Glu Ser Pro Pro 1 5 10 15Gln Glu Asn Ser Cys Leu Asp Pro Pro Asp Arg Asp Pro Asn Cys Lys 20 25 30Pro Pro Pro Val Lys Pro His Ile Phe Thr Thr Arg Ser Arg Thr Arg 35 40 45Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Ser Pro Leu Asp Cys Pro 50 55 60Tyr Glu Glu Gly Gly Leu Ala Ser Cys Pro Ile Ile Thr Val Ser Ser 65 70 75 80Val Leu Thr Ile Gln Arg Pro Gly Asp Gly Pro Ala Ser Val Arg Pro 85 90 95Ser Ser Gln Asp Ser Val Ser Ala Gly Glu Lys Pro Pro Arg Leu Tyr 100 105 110Asp Arg Arg Ser Ile Phe Asp Ala Val Ala Gln Ser Asn Cys Gln Glu 115 120 125Leu Glu Ser Leu Leu Pro Phe Leu Gln Arg Ser Lys Lys Arg Leu Thr 130 135 140Asp Ser Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu Lys145 150 155 160Ala Met Leu Asn Leu His Asn Gly Gln Asn Asp Thr Ile Ala Leu Leu 165 170 175Leu Asp Val Ala Arg Lys Thr Asp Ser Leu Lys Gln Phe Val Asn Ala 180 185 190Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile Ala 195 200 205Ile Glu Arg Arg Asn Met Thr Leu Val Thr Leu Leu Val Glu Asn Gly 210 215 220Ala Asp Val Gln Ala Ala Ala Asn Gly Asp Phe Phe Lys Lys Thr Lys225 230 235 240Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala Ala 245 250 255Cys Thr Asn Gln Leu Ala Ile Val Lys Phe Leu Leu Gln Asn Ser Trp 260 265 270Gln Pro Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val Leu 275 280 285His Ala Leu Val Glu Val Ala Asp Asn Thr Val Asp Asn Thr Lys Phe 290 295 300Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu His305 310 315 320Pro Thr Leu Lys Leu Glu Glu Ile Thr Asn Arg Lys Gly Leu Thr Pro 325 330 335Leu Ala Leu Ala Ala Ser Ser Gly Lys Ile Gly Val Leu Ala Tyr Ile 340 345 350Leu Gln Arg Glu Ile His Glu Pro Glu Cys Arg His Leu Ser Arg Lys 355 360 365Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp Leu 370 375 380Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile Ala385 390 395 400Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val Glu 405 410 415Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys Arg 420 425 430Ile Phe Tyr Phe Asn Phe Phe Val Tyr Cys Leu Tyr Met Ile Ile Phe 435 440 445Thr Ala Ala Ala Tyr Tyr Arg Pro Val Glu Gly Leu Pro Pro Tyr Lys 450 455 460Leu Lys Asn Thr Val Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu465 470 475 480Ser Val Ser Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe 485 490 495Leu Gln Arg Arg Pro Ser Leu Lys Ser Leu Phe Val Asp Ser Tyr Ser 500 505 510Glu Ile Leu Phe Phe Val Gln Ser Leu Phe Met Leu Val Ser Val Val 515 520 525Leu Tyr Phe Ser Gln Arg Lys Glu Tyr Val Ala Ser Met Val Phe Ser 530 535 540Leu Ala Met Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln545 550 555 560Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp 565 570 575Leu Cys Arg Phe Met Phe Val Tyr Leu Val Phe Leu Phe Gly Phe Ser 580 585 590Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asn Ser Leu Pro 595 600 605Met Glu Ser Thr Pro His Lys Cys Arg Gly Ser Ala Cys Lys Pro Gly 610 615 620Asn Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys Phe625 630 635 640Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe Lys 645 650 655Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr Ile 660 665 670Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn Lys 675 680 685Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile Thr 690 695 700Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala Phe705 710 715 720Arg Ser Gly Lys Leu Leu Gln Val Gly Phe Thr Pro Asp Gly Lys Asp 725 730 735Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr Trp 740 745 750Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu Gly 755 760 765Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Gly Arg Val Ser Gly 770 775 780Arg Asn Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Asp Ala Ser785 790 795 800Thr Arg Asp Arg His Ala Thr Gln Gln Glu Glu Val Gln Leu Lys His 805 810 815Tyr Thr Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Asp Ser 820 825 830Met Val Pro Gly Glu Lys 835 4 44 DNA Homo sapiens 4gcagcacata tggtcagtct ctggtggcta gcctgtcctg acag 44 5 46 DNA Homo sapiens 5gcagcaggta cctcagttgg actggaggag ctggacgggc acatag 46 6 53 DNA Homo sapiens 6gcagcaagat ctgccatcat ggtcagtctc tggtggctag cctgtcctga cag 53 7 46 DNA Homo sapiens 7gcagcatcta gatcagttgg actggaggag ctggacgggc acatag 46 8 733 DNA Homo sapiens 8gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga 120tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg 180tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg 360agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga 540ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg 600acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720gactctagag gat 733 9 468 DNA Homo sapiens Unsure 23 May be any nucleotide 9aattccgtga aaatatatat ttnccaccag aattcactgg gaccccagag ccagcagatg 60tggttggaaa gatcctctgc tctgtcctct ggcctcctgc tgcatctggg ccatcagttg 120gactggagga gctggacggg cacatagttt tcctcagagg caccatcctc atcctccttg 180ggaggggaag ccaggacagg gttctcgaga gttcgaggga cacctgcccc tgacgggtcc 240tcacacagcg taggcagcgt ctgctcccat gaagcccagt tcaactcctc caccctgaag 300caccagcgnt tcatcggggc tgccatcttg gcttagtgcc aaggttcagc atcaaaactg 360cccgttgttt tttnctgnaa caccatagnc attttccatt ttcaggacag agatggtttt 420tgnagttcca atgnttcagt ttnantgggg aaattttgac ggtntggt 468 10 319 DNA Homo sapiens Unsure 8 May be any nucleotide 10ttccaggngc agctgcactt ccgcggcatg gtgctgctgc tgctgctggc ctacgtnctg 60ctcacctaca tcctgctgct caacatgctc atcgccctca tgagcgagac cgtcaacagt 120gtcgccactg acagctggag catctggaag ctgcagaaag cnatctntgt cctggagatg 180gagaatggct attggtggtg caggaagaag cagcgggcag gtgtgatgct gaccgttggc 240actaagccag atggcagccc cgatgagcgc tggtgcttca gggtngagga ggtgaactgg 300gcttcatggg gagcagacg 319 11 299 DNA Homo sapiens Unsure 83 May be any nucleotide 11ttcaggactg agccaccttt cccgaaagtt caccgagtgg tgctatgggc ctgtccgggt 60gtcgctgtat gacctggctt ctntggacag ctgtnaggag aactcagtgc tggagatcat 120tgcctttcat tgcaagagcc cgcaccgaca ccgaatggtc gttttggagc ccctgaacaa 180actgctgcag gcggaaatgg gatctgctca tccccaagtt cttcttaaac ttcctgtgta 240atctgatcta catgttcatc ttcaacgctg ttgcctacca tcagcctacc ctgaagaag 299 12 466 DNA Homo sapiens Unsure 297 May be any nucleotide 12aattcggcag aggccacgcc ctggcctcag cctgcggggc tccagtcagg ccaacaccga 60cgcgcatggg aggaagacag gacccttgac atctccatct gcacagaggt cctggctgga 120ccagacagcc tcctcctcct aggatgacct caccctccag ctctccagtt ttcaggttgg 180agacattaga tggaggccaa gaagatggct ctgaggcgga cagaggaaag ctggattttg 240ggagcgggct gcctcccatg gagttcacag ttccagggcg aggaccggaa atttggncct 300tcagataaga gtcaacctca antaccgaaa gggaacaggt gccattcagc cggattccaa 360accgtttttg accggatcgg ttttttnaat ggggttttcc ggggtnttcc cgaggatttg 420gttgganttc caggtactna gcaagaccag aatacttacg nttggt 466 13 497 DNA Homo sapiens Unsure 112 May be any nucleotide 13aattcggcac gagatcctgc gggacctgct gcgcttcctt ctgatctact tagtcttcct 60tttcggcttc gctgtagccc tggtgagcct gagccaggag gcttggcgcc cnggaagctc 120ctacaggcnc cattgccaca gagtcagtgc agcccatgga gggacaggag gacgagggca 180acggggccca gtacaggggt atcctggnaa gcctccttgg agctcttnaa attcaccatc 240ggcatgggcg agctggcctt ccaggagcag ctgcacttcc gcggcatggt gctgctgntg 300ctgttgggnt tangtgctgc tcanctacat ccngttgctt caacatgttc atnggccttc 360atggagcgag ancgttaaaa aattnttggn caattnaana nttgggngca ttttggaagt 420ttgnaagaaa gncatttttn tccntgggga tgggggaatg ggtttntttg ggggttcaag 480naggaangca anggggn 497 14 362 DNA Homo sapiens Unsure 305 May be any nucleotide 14ggcagagact gcagtgtgtg aagctcctgg tggagaatgg ggccaatgtg catgcccggg 60tctgcggcga cttcttccag aagggccaag ggacttgctt ttatttcggt gaagctaccc 120ctctctttgg ccgcttgcac caagcagtgg gatgtggtaa gctacctcct ggagaaccca 180caccagcccg ccagcctggc aggccactgg actcccaggg gcaacacagt cctgcatgcc 240ctagtggatg gatctcggga caacttcagc tgaggaacat tgcactggtg gaccagcatg 300tatgnttggg ntccttccaa ggttgggggc ccgtctttgn ccctaacntg gcaatttnnn 360gg 362 15 187 DNA Homo sapiens Unsure 22 May be any nucleotide 15ggcagaggga aattcgcccc tnaaataaga gtcaacctca actaccgaaa ggaaacaggt 60gccagtaagc cggatccaaa ccgatttaac cgagatcggc tcttcantgc ggtctcccgg 120ggtgtcccna aggntctggc tggacttccn nagtacctga agccaagacc agncaagtac 180ctnaccg 187 16 298 DNA Homo sapiens Unsure 40 May be any nucleotide 16gccacgccct ggcctcagcc tgcgggggct ccagtcaggn caacaccgac gcgcactggg 60gaggaanaac angacccttg nncatctcca tctgcacaga ngtcctggnt gggaccgagc 120aagcctcctc ctcctaagga tgacctcacc ctnnaagntt cncnagtttt caagttggna 180gacattagat ggaannnaag aaagatgggt ctgaagcgga caganggaaa actggatttt 240ngaacngggt aggttcccaa tggagtaaca ntttccaagg gngaaggacc gggaaatt 298 17 534 DNA Homo sapiens Unsure 3 May be any nucleotide 17gcnncaggca cgaccctgac catggccacc gggtccatac tcaatccata ctctagtccc 60atccaagacg gggatcatgc caagggcctc gtggcaacca tccaggtcct ctctgttaac 120cagcatctca tttggagggc aagcccctta gtcacactgt agctgggagg gttggcgtga 180ggtcctttgg ggctcctggg gtgtggaagc ctgctccctg tcctctctcc tcatttcctg 240ggcccttgct ttgatcttga catggagtgg gcagcctatt tgcaattgtt gagtgtaccc 300atggctctcc cctccccaac ccagcaacga caccgaaggt cgttttggag cccctgaaca 360aatgctgcag ggaaagggga tctgctcatc ccaatnnttc taaatttcng tgtaatccga 420tccaaaagtt canntcaacg gtgntggcta acaacagcta accgaagaag gcaaggcgtg 480aagtttgggg ggcaaatntg ggggnaggct gcttgnaaaa aacngggggg aaaa 534 18 496 DNA Homo sapiens Unsure 44 May be any nucleotide 18gacaggggag agttaagctc ccggttctcc accgtgccgg ctgncanggt gggctgaggg 60tgaccgagag accagaacct gcttgctgga gcttagtgct cagagctggg gagggaggtt 120ccgccgctcc tctgctgtca gcgccggcag cccctcccgg cttcacttcc tcccgcagcc 180cctgctactg agaagctccg ggatcccagc agccgccacg ccctggcctc agcctgcggg 240gctccagtca ggccaacacc gacgcgcant ggngaggaag acaggaccct tgacatctcc 300atctgcacag aggtcctggc tggaccgagc agcctcctcc tcctaggatg acctcaccct 360ccagctctcc agttttcagg ttggagacat tagatggagg ccaagaagat ggctctgagg 420cggacagagg aaagctggat tttgggagcg ggctgcntcc catggagtca cagttccagg 480gcgaggaccg gaaatt 496 19 454 DNA Homo sapiens 19aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtccctgtc gatctgcagc agtggcagaa tgcaggcatt 120gactccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacacccc gggagaccgc attgaagagc cgatctcggt caaatcggtt 300tggatccggc tgactggcac ctgttccctt tcggtagttg aggttgactc ttatctgagg 360ggcgaatttc cggtcctcgc cctggaactg tgactccatg ggaggcagcc cgctcccaaa 420atccagcttt cctctgtccg cctcagagcc atct 454 20 461 DNA Homo sapiens Unsure 96 May be any nucleotide 20tcggtgagct acccctctct ttggccgctt gcaccaagca gtgggatgtg gtaagctacc 60tcctggagaa cccacaccag cccgccagcc tgcagncact gactcccagg gcaacacagt 120cctgcatgcc ctagtgatga tctcggacaa ctcagctgag aacattgcac tggtgaccag 180catgtatgat gggctcctcc aagctggggc ccgcctctgc cctaccgtgc agcttgagga 240catccgcaac ctgcaggatc tcacgcctct gaagctggcc gccaaggagg gcaagatcga 300gattttcagg cacatcctgc agcgggagtt ttcaggactg agccaccttt cccgaaagtt 360caccgagtgg tgctatgggc ctgtccgggt gtcgctgtat gacctggctt ctgtggacag 420ctgtgaggag aactcagtgc tggagatcat tgcctttcaa n 461 21 478 DNA Homo sapiens Unsure 77 May be any nucleotide 21gctagcctgt cctgacaggg agagttaagc tcccgttctc caccgtgccg gctggcaggt 60gggctgaggg tgaccgngag accagaacct gcttgctgga gcttagtgct cagagctggg 120gagggaggtt ccgccgctcc tctgctgtca gcgccggcag cccctcccgg cttcacttcc 180tcccgcagcc cctgctactg agaagctccg ggatcccagc agccgccacg ccctggcctc 240agcctgcgng gctccagtca ggccaacacc gacgcgcant ggngaggaag acaggaccct 300tgacatctcc atctgcacag aggtcctggc tggacgangc agcctcctcc tcctaggatg 360acctcaacct ccagctctcc agttttcagg ttggagacat tagatggagg ccaagaagat 420ggctctgagg cggacagagg aaagctggat tttgggaagc gggctgcctc ccatggnt 478 22 433 DNA Homo sapiens Unsure 312 May be any nucleotide 22attcactggg accccagagc cagcagatgt ggttggaaag atcctctgct ctgtcctctg 60gcctcctgct gcatctgggc catcagttgg actggaggag ctggacgggc acatagtttt 120cctcagaggc accatcctca tcctccttgg gaggggaagc caggacaggg ttctcgagag 180ttcgagggac acctgcccct gacgggtcct cacacagcgt aggcagcgtc tgctcccatg 240aagcccagtt cacctcctcc accctgaagc accagcgctc atccgggctg ccatctggct 300tagtgccaac gntcagcatc acacctgccc gctgcttctt nctgcaccac caatagccat 360tctccatctc caggacagga gatggctttc tgcagcttcc agatgctcca gctgtcagtg 420gcgacantgt tga 433 23 430 DNA Homo sapiens 23aatggcgatg tgcagacgct gtggcctcgg taatagtcat ctgtgcactg ggcatttacc 60aggggctgag gattgccaga gtccctgtcg atctgcagca gtggcagaat gcaggcattg 120accccgtcct taaggttcag cacagccttc atcaggcacg tcttacctgt ggagccctct 180gtgtattccg agtcggtgag gtacttgctg gtcttgctca ggtactctgg aagtccagcc 240agatcctcgg ggacaccccg ggagaccgca ttgaagagcc gatctcggtc aaatcggttt 300ggatccggct gactggcatc tgttcccttt cggtagttga ggttgactct tatctgaggg 360gcgaatttcc ggtcctcgcc ctggaactgt gactccatgg gaggcagccc gctcccaaaa 420tccagctttc 430 24 408 DNA Homo sapiens 24aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtcccggtc gatctgcagc agtggcagaa tgcaggcatt 120gaccccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacacccc gggagaccgc attgaagagc cgatctcggt caaatcggtt 300tggatccggc tgactggcac ctgttccctt tcggtagttg aggttgactc ttatctgagg 360ggcgaatttc cggtcctcgc cctgggaact gtgactccat gggaggca 408 25 422 DNA Homo sapiens Unsure 7 May be any nucleotide 25ttcttcnggg taggctgatg gtaggcaaca gagttgaaga tgaacatgta gatcagatta 60cacaggaagt ttaagaagaa cttggggatg agcagatccc atttcgcctg cagcagtttg 120ttcaggggct ccaaaacgac cattcggtgt cggtgcgggc tcttgcaatg aaaggcaatg 180atctccagca ctgagttctc ctcacagctg tccacagaag ccaggtcata cagcgacacc 240cggacaggcc catagcacca ctcggtgaac tttcgggaaa ggtggctcag tcctganaac 300tccccgctgc aggatgtgcc tgaaaatctc gatcttgccc tccttggcgg ccantttcag 360aggcgtgaga tcctgcaggt tgcggatgtc ctcaagctgc acggtagggc agagggcggg 420cc 422 26 424 DNA Homo sapiens 26gtttttgagg ttagtgaaaa tatatatttg ccaccagaat tcactgggac cccagagcca 60gcagatgtgg ttggaaagat cctctgctct gtcctctggc ctcctgctgc atctgggcca 120tcagttggac tggaggagct ggacgggcac atagttttcc tcagaggcac catcctcatc 180ctccttggga ggggaagcca ggacagggtt ctcgagagtt cgagggacac ctgcccctga 240cgggtcctca cacagcgtag gcagcgtctg ctcccatgaa gcccagttca cctcctccac 300cctgaagcac cagcgctcat ccgggctgcc atctggctta gtgccaacgg tcagcatcac 360acctgcccgc tgcttcttcc tgcaccacca atagccattc tccatctcca ggacagagat 420ggct 424 27 432 DNA Homo sapiens Unsure 149 May be any nucleotide 27tgtttcctgg ccatcgagtg gtacctgccc ctgcttgtgt ctgcgctggt gctgggctgg 60ctgaacctgc tttactatac acgtggcttc cagcacacag gcatctacag tgtcatgatc 120cagaagccct ggtgagcctg agccaggann ttggcgcccc gaagctccta caggccccaa 180tgccacagag tcagtgcagc ccatggaggg acaggaggac gagggcaacg gggcccagta 240caggggtatc ctggaagcct ccttggagct cttcaaattc accatcggca tgggcgagct 300ggccttccag gagcagctgc acttccgcgg catgggtgct gctgctgctn ctggcctacg 360tgctgctcac ctacatcctg ctgctcaaca tgctcatcgc cctcatggag cgagaccgtc 420aacaggtntc gc 432 28 383 DNA Homo sapiens 28aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtccctgtc gatctgcagc agtggcagaa tgcaggcatt 120gactccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacacccc gggagaccgc attgaagagc cgatctcggt caaatcggtt 300tggatccggc tgactggcac ctgttccctt tcggtagttg aggttgactc ttatctgagg 360ggcgaatttc cggtcctcgc cct 383 29 375 DNA Homo sapiens 29aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtccctgtc gatctgcagc agtggcagaa tgcaggcatt 120gaccccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacacccg ggagaccgca ttgaagagcc gatctcggtc aaatcggttt 300ggatccggct gactggcacc tgttcccttt cggtagttga ggttgactct tatctgaggg 360gcgaatttcc ggtcc 375 30 463 DNA Homo sapiens Unsure 21 May be any nucleotide 30gagaggtcct ggctggacca ngcagcctcc tcctcctagg atgacctcac cctccagctc 60tccagttttc aggttggaga cattagatgg aggccaagaa gatggctctg aggcggacag 120aggaaagctg gattttggga gcgggctgcc tcccatggag tcacagttcc agggcgagga 180ccggaaattc gcccctcaga taagagtcaa cctcaactac cgaaagggaa caggtgccag 240tcagccggat ccaaaccgat ttgaccgaga tcggctcttc aatgcggtct cccggggtgt 300ccccnaggat ctggctggac ttccagagta cctgagcaag accagcaagt accttaccga 360cttggaatta cacagagggc ttccacaggt taagacgttg cctgatggaa ggctgtgttg 420aactttaagg acggggttca attgcttgct ttntgccatt gtt 463 31 484 DNA Homo sapiens Unsure 300 May be any nucleotide 31ggtgagctac ccctctcttt ggccgcttgc accaagcagt gggatgtggt aagctacctc 60ctggagaacc cacaccagcc cgccagcctg caggcactga ctcccagggc aacacagtcc 120tgcatgccct agtgatgatc tcggacaact cagctgagaa cattgcactg gtgaccagca 180tgtatgatgg gctcctccaa gctggggccc gcctctgccc taccgtgcaa gcttgaggac 240atccgcaacc tgcaggatct cacgcctctg aaagctggcc gccaaggagg gcaagatcgn 300gattttcaag gcacatcctt gcaagcggga gttttcagga ctgaagccac cttttccccg 360aaagttcacc gagtggtggc taatggggcc tgtccgggtt gtcgctgtaa tgacctgggc 420tttctgtgga cagctgtgag gagaactcag tgctgggaat cattgccttt catttgcaaa 480agcc 484 32 370 DNA Homo sapiens 32aatggcgatg tgcagacgct gtggcctcgg taatagtcat ctgtgcactg ggcatttacc 60aggggctgag gattgccaga gtcccggtcg atctgcagca gtggcagaat gcaggcattg 120accccgtcct taaggttcag cacagccttc atcaggcacg tcttacctgt ggagccctct 180gtgtattccg agtcggtgag gtacttgctg gtcttgctca ggtactctgg aagtccagcc 240agatcctcgg ggacaccccg ggagaccgca ttgaagagcc gatctcggtc aaatcggttt 300ggatccggct gactggcacc tgttcccttt cggtagttga ggttgactct tatctgaggg 360gcgactcgtg 370 33 375 DNA Homo sapiens 33gcagccgcac gccctggcct cagcctgcgt ggctccagtc aggccaacac cgacgcgcac 60tggcgaggaa gacaggaccc ttgacatctc catctgcaca gaggtcctgg ctggccgagc 120agcctcctcc tcctaggatg acctcaccct ccagctctcc agttttcagg ttggagacat 180tagatggagg ccaagaagat ggctctgagg cggacagagg aaagctggat tttgggagcg 240ggctgcctcc catggagtca cagttccagg gcgaggaccg gaaattcgcc cctcagataa 300gagtcaacct caactaccga aaggaacagg tgccagtcag ccggatccaa accgatttga 360ccgagatcgg ctctt 375 34 401 DNA Homo sapiens Unsure 275 May be any nucleotide 34aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtcccggtc gatctgcagc agtggcagaa tgcaggcatt 120gaccccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacacccc ggggagaccg cattnaagag ccgatcttgg gtcaaatcgg 300tttggatccg gctgactggc acctgttccc tttcggtagt tgaggttgac tcttattctg 360aggggngcga attttncggt ccttcgccng gggaantttg a 401 35 463 DNA Homo sapiens Unsure 420 May be any nucleotide 35agaggtcctg gctggacatg cagcctcctc ctcctaggat gacctcaccc tccagctctc 60cagttttcag gttggagaca ttagatggag gccaagaaga tggctctgag gcggacagag 120gaaagctgga ttttgggagc gggctgcctc ccatggagtc acagttccag ggcgaggacc 180ggaaattcgc ccctcagata agagtcaacc tcaactaccg aaagggaaca ggtgccagtc 240agccggatcc aaaccgattt gaccgagatc ggctcttcaa tgcggtctcc cggggtgtcc 300ccgaggatct ggctggactt ccagagtacc tgagcaagac cagcaagtaa cctcaccgac 360ttggaattac acagaggggt tccacaggtt aagacgttgc ctgattgaaa gggttgttgn 420tgaaacttta aggacggggg tcaattgcnt gcatttttgc ctt 463 36 374 DNA Homo sapiens Unsure 112 May be any nucleotide 36aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtcccggtc gatctgcagc agtggcagaa tncaggcatt 120gaccccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacacccc gggagaccgc atttgaagag ccgatctcgg tcaaatcagg 300tttggatccg gctgactngg cacctgttcc ctttcggtag tttgaggttg actcttatct 360gaggggcgaa tttc 374 37 401 DNA Homo sapiens Unsure 267 May be any nucleotide 37aatcggcgat gtgcagaggc tcgtggcctc ggtaatagtc atctgtgcac tgggcattta 60ccaggggctg aggattgcca gagtccctgt cgatctgcag cagtggcaga atgcaggcat 120tcgactccgt ccttaaggtt cagcacagcc ttcatcaggc acgtcttacc tgtggagccc 180tctgtgtatt ccgagtcggt gaggtacttg ctggtcttgc tcaggtactc tggaagtcca 240gccagatcct cggggacacc ccgggangac cgcattgaag agccgatctc ggtcaaatcg 300gtttggatcc ggctgacttg gcacctgttc ccnttcggta gttgaggttg antcttatct 360gagggggcga atttccggtc ctcgccctgg aactgtgact c 401 38 403 DNA Homo sapiens Unsure 179 May be any nucleotide 38agtgaaaata tatatttgcc accagaattc actgggaccc cagagccagc agatgtggtt 60ggaaagatcc tctgctctgt cctctggcct cctgctgcat ctgggccatc agttggactg 120gaggagctgg acgggcacat agttttcctc agaggcacca tcctcatcct ccttgggang 180gcgaagccag gacagggttc tcgagagttc gagggacacc tgcccctgac gggtcctcac 240acagcgtagg cacgcgtctg ctcccatgaa gcccaagttc acctcctcca ccctgaagca 300ccaagcgctt cattcggggc tgccatctgg ctttagtgcc aacggtcagc atcacacctg 360cccgctgctt tcttcctgca ccaccaatag ccattctcca tct 403 39 406 DNA Homo sapiens Unsure 18 May be any nucleotide 39agaggtcctg gctggacncg cagcctcctc ctcctaggat gacctcaccc tccagctctc 60cagttttcag gttggagaca ttagatggag gccaagaaga tggctctgag gcggacagag 120gaaagctgga ttttgggagc gggctgcctc ccatggagtc acagttccag ggcgaggacc 180ggaaattcgc ccctcagata agagtcaacc tcaactaccg aaagggaaca ggtgccagtc 240agccggatcc aaaccgattt gaccgagatc ggcttcttca atgcggtctc ccggggtgtc 300cccgaggatc tggctgggat ttccagagta accttgagca agaccagcaa gtnacttcac 360cgatttggga ataanacaga ggggtttcca gaagtnaagg antttg 406 40 319 DNA Homo sapiens Unsure 8 May be any nucleotide 40ttccaggngc agctgcactt ccgcggcatg gtgctgctgc tgctgctggc ctacgtnctg 60ctcacctaca tcctgctgct caacatgctc atcgccctca tgagcgagac cgtcaacagt 120gtcgccactg acagctggag catctggaag ctgcagaaag cnatctntgt cctggagatg 180gagaatggct attggtggtg caggaagaag cagcgggcag gtgtgatgct gaccgttggc 240actaagccag atggcagccc cgatgagcgc tggtgcttca gggtngagga ggtgaactgg 300gcttcatggg gagcagacg 319 41 423 DNA Homo sapiens Unsure 23 May be any nucleotide 41acaggggaga gttaagctcc cgntctccac cgtgccggct gncaggtggg ctgagggtna 60ccgagagacc agaacctgct tgctggagct tagtgctcag agctggggag ggaggttccg 120ccgctcctct gctgtcagcg ccggcagccc ctcccggctt cacttcctcc cgcagcccct 180gctactgaga agctccggga tcccagcagc cgccacgccc tggcctcagc ctgcggggct 240ccagtcaggc caacaccgac gcgcantggn gaggaagaca ggacccttga catctccatc 300tgcacagagg tcctggctgg acgagcagcc tcctcctcct tagggatgaa ctnaaccttc 360caagctcttc cagtttttaa ggtttggaga acatttagat tggagggcca agaagantgg 420ctt 423 42 386 DNA Homo sapiens Unsure 304 May be any nucleotide 42aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtcccggtc gatctgcagc agtggcagaa tgcaggcatt 120gaccccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacacccc ggggagaccg cattgaagag ccgatcttgg gtcaaatcgg 300tttngatccn gctgactngg cacctgtttc cctttcggta gtttnaggtt gaattttatt 360ctgagggggc gaattttccg gtcctc 386 43 294 DNA Homo sapiens 43tcggtgagct acccctctct ttggccgctt gcaccaagca gtgggatgtg gtaagctacc 60tcctggagaa cccacaccag cccgccagcc tgcaggccac tgactcccag ggcaacacag 120tcctgcatgc cctagtgatg atctcggaca actcagctga gaacattgca ctggtgacca 180gcatgtatga tgggctcctc caagctgggg cccgcctctg ccctaccgtg cagcttgagg 240acatccgcaa cctgcaggat ctcacgcctc tgaagctggc cgccaaggag ggca 294 44 326 DNA Homo sapiens Unsure 26 May be any nucleotide 44gagaactcag tgctggagat cattgncttt cattgcaaga gcccgnaccg acaccgaatg 60gtcgttttgg agcccctgaa caaactgctg caggcgaaat gggatctgct catccccaag 120ttcttcttaa acttcctgtg taatctgatn tacatgttca tcttcaccgc tgttgcctac 180catcagccta ccctgaagaa gcaggccgcc cctcacctga aagcggaggt tggaaactcc 240atgctgctga cgggccacat ccttatcctg ctagggggga tctacctcct cgtggggcaa 300naagtggnaa attttggggg ggnaat 326 45 299 DNA Homo sapiens Unsure 83 May be any nucleotide 45ttcaggactg agccaccttt cccgaaagtt caccgagtgg tgctatgggc ctgtccgggt 60gtcgctgtat gacctggctt ctntggacag ctgtnaggag aactcagtgc tggagatcat 120tgcctttcat tgcaagagcc cgcaccgaca ccgaatggtc gttttggagc ccctgaacaa 180actgctgcag gcggaaatgg gatctgctca tccccaagtt cttcttaaac ttcctgtgta 240atctgatcta catgttcatc ttcaacgctg ttgcctacca tcagcctacc ctgaagaag 299 46 451 DNA Homo sapiens 46attcggcaca ggctcttcag tgtggtctcc cggggtgtcc caggagctga ctggactgct 60agagtacctg cgccggacca gcaagtacct cactgactcg gcatacacag aaggctccac 120tggaaagacg tgcctgatga aggctgtgct gaaccttcag gatggggtca atgcctgtat 180cctgccgctg ctgcagattg acagggattc cggcaatcct cagccccttg tcaatgccca 240gtgcaccgat gagttctacc gaggccacag tgcgctgcac atcgccatag agaagaggag 300cctgtggtgc gtgaactgct ggtagagaat ggagcgaatg ttcacatccg agcctgtggc 360gcttcttcca aaagcaccaa ggaacttgtt tctattttgg gagagctacc tctttctctg 420gcagcgtgca ccaagcagtg ggatgtggtg a 451 47 305 DNA Homo sapiens Unsure 256 May be any nucleotide 47gagttagtga aaatatatat ttgccaccag aattcactgg gaccccagag ccagcagatg 60tggttggaaa gatcctctgc tctgtcctct ggcctcctgc tgcatctggg ccatcagttg 120gactggagga gctggacggg cacatagttt tcctcagagg caccatcctc atcctccttg 180ggaggggaag ccaggacagg gttctcgaga gttcgaggga cacctgcccc tgacgggtcc 240tcacacagcg taggangcgt ctgctcccat gaagcccagt tcacctcctc caccctgaag 300cacca 305 48 333 DNA Homo sapiens Unsure 259 May be any nucleotide 48gagttagtga aaatatatat ttgccaccag aattcactgg gaccccagag ccagcagatg 60tggttggaaa gatcctctgc tctgtcctct ggcctcctgc tgcatctggg ccatcagttg 120gactggagga gctggacggg cacatagttt tcctcagagg caccatcctc atcctccttg 180ggaggggaag ccaggacagg gttctcgaga gttcgaggga cacctgcccc tggacgggtc 240ctcacacagc gtaggcagng tctgctccca tgaagcccag ttcacctcct ccaccctgaa 300gcaccagcgc ctcatccggg ctgcnatctt ggt 333 49 317 DNA Homo sapiens Unsure 26 May be any nucleotide 49cagcctcctc ctcctaggat gacctnaccc tccagctctc cagttttcag gttggagaca 60ttagatggag gccaaganga tggctctgag gcggacagag gaaagctgga tttngggagc 120gggctgcctc ccatggagtc acagttccag ggcgaggacc ggaaattcgc ccctcagata 180agagtcaacc tcaactaccg aaaggaacag gtgccagtca gncggatcca aaccgatttg 240accgagatcg gctcttcaat gcggtctccc tggggtgtnc ccgaaggatc ttggctngac 300tttcagagta cctgagc 317 50 379 DNA Homo sapiens 50aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtcccggtc gatctgcagc agtggcagaa tgcaggcatt 120gaccccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tggagccctc 180tgtgtattcc gagtcggtga ggtacttgct gggtcttgct cagggtactc tgggaagtcc 240agccagatcc tcggggacac cccggggagg accgcattga aggagccgat ctcgggtcaa 300atcggtttgg gatccgggct gactgggcac ctgttccctt tcggtagttg agggttgact 360cttaatctga ggggggcga 379 51 357 DNA Homo sapiens Unsure 313 May be any nucleotide 51aatggcgatg tgcagagcgc tgtggcctcg gtaatagtca tctgtgcact gggcatttac 60caggggctga ggattgccag agtcccggtc gatctgcagc agtggcagaa tgcaggcatt 120gaccccgtcc ttaaggttca gcacagcctt catcaggcac gtcttacctg tgggagccct 180ctgtgtattc cgagtcggtg aggtacttgc tggtcttgct caggtactct gggaagtcca 240gccagatcct cggggacacc ccggggagac cgcattgaag gagccgatct tcgggtcaaa 300tcggttttgg atnccggctg acttggcanc tgtttccntt tcggtagttt gaggttg 357 52 463 DNA Homo sapiens 52ctccccctgt tagtgtcatc cctagtgctg ggctggctga acctgcttta ttatacacgt 60ggctttcagc acacaggcat ctacagtgtc atgatccaaa aggtcattct gcgagacctg 120ctccgcttcc tgctggtcta cctagtcttc cttttcggct ttgctgtagc cctagtaagc 180ttgagccggg acggccgaag tcccaaagcc cctgaagata gcaacaccac tgtgacggaa 240aagcccacgc tgggtcagga ggaggagcca gtcccatatg ggggcattct ggatgctccc 300tagagctgtt caagttcacc attggtatgg gtgagctggc tttccaggaa cagctgcctt 360tcgtggggtg gtgctgctgt tgctgttggc ctacgtcctc ctcacctacg tcctactgct 420caacatgctc attgccctca tgagtgagac tgtcaacagc gtt 463 53 354 DNA Homo sapiens Unsure 290 May be any nucleotide 53aatggcgatg tgcagaggct gtggcctcgg taatagtcat ctgtgcactg ggcatttacc 60aggggctgag gattgccaga gtcccggtcg atctgcagca gtggcagaat gcaggcattg 120accccgtcct taaggttcag cacagccttc atcaggcacg tcttacctgt gggagccctc 180tgtgtattcc gagtcggtga ggtacttgct ggtcttgctc aggtactctg gaagtccagc 240cagatcctcg gggacaaccc gggaggaccg cattgaagga gccgattttn ggtcaaaatc 300gggtttggat nccggttnat ttgggaaccg tttccctttt gggtagtttt aggg 354 54 275 DNA Homo sapiens Unsure 16 May be any nucleotide 54agaggtcctg gctggnaccg agcagcctcc tcctcctagg atgacctcac cctccagctc 60tccagttttc aggttggaga cattagatgg aggccaagaa gatggctctg aggcggacag 120aggaaagctg gattttggga gcgggctgcc tcccatggag tcacagttcc agggcgagga 180ccggaaattc gcccctcaga taagagtcaa cctcaactac cgaaagggan caggtgccag 240taanccgggt ccaaaccgat ttnaccaaga tcggg 275 55 256 DNA Homo sapiens 55aatggcgatg tgcagacgct gtggcctcgg taatagtcat ctgtgcactg ggcatttacc 60aggggctgag gattgccaga gtccctgtcg atctgcagca gtggcagaat gtaggcattg 120actccgtcct taaggttcag cacagccttc atcaggcacg tcttacctgt ggagccctct 180gtgtattccg agtcggtgag gtacttgctg gtcttgctca ggtactctgg aagtccagcc 240agatcctcgg ggacac 256 56 220 DNA Homo sapiens 56acgagggcaa cggggcccag tacaggggta tcctggtagc ctccttggag ctcttcaaat 60tcaccatcgg catgggcgag ctggccttcc aggagcagct gcacttccgc ggcatggtgc 120tgctgctgct gctggcctac gtgctgctca cctacatcct gctgctcaac atgctcatcg 180ccctcatgag cgagaccgtc aacagtgtcg ccactgacag 220 57 444 DNA Homo sapiens Unsure 6 May be any nucleotide 57tagttngtga aaatatatat ttgccaccag aattcactgg gaccccagag ccagcagatg 60tggttggaaa gatcctctgc tctgtcctct ggcctcctgc tgcatctggg ccatcagttg 120gactggagga gctggacggg cacatagttt tcctcagagg caccatcctc atcctccttg 180ggaggggaag ccaggacagg gttctcgaga gttcctgtaa acagatggca agcactgtag 240cttaaccctt gagtgtgtcc ccaggaagca ggcaccaggg aaacggggcc acagtcatga 300aaacacgtca tgccgtgggg acagcctcag cgatcctggg aggccagcaa tccttctccc 360tgcttccctc actncacaag catttcccaa tccccttgcc atatccaggg gntttcccct 420tgnccccttt ncaccctcaa gggg 444 58 200 DNA Homo sapiens Unsure 192 May be any nucleotide 58gtgagttagt gaaaatatat atttgccacc agaattcact gggaccccag agccagcaga 60tgtggttgga aagatcctct gctctgtcct ctggcctcct gctgcatctg ggccatcagt 120tggactggag gagctggacg ggcacatagt tttcctcaga ggcaccatcc tcatcctcct 180tgggagggga anccaggacg 200 59 369 DNA Homo sapiens Unsure 27 May be any nucleotide 59agagccagca gatgtggttg gaaagancct ctgctctgtc ctctggcctn ctgctgcatc 60tgggccatca gttggactgg aggagctgga cgggcacata gttttcctca gaggcaccat 120cctcatcctc cttgggaggt gaagccagga cagggttctc gagagttcct gtaaacagat 180ggcaagcact ntagcttaac ccttgagtgt gtccccagga agcangcacc agggaaacgg 240ngccacagtc atgaaaacac gtcatgccgt ngggacagcc tcagcgatcc tggaaggcca 300gcaatccttc tccctgcttc cctcactnca caaggcattt cccaatcccn tgccntttca 360gggnttttc 369 60 322 DNA Homo sapiens Unsure 17 May be any nucleotide 60gggaagaatc cccatcnatg gcagcttcca tgggtggcaa gtccccagca tccaagggct 60gcctctgagn gtcacccacc cccacctgag accttagtgg ctagaatnng ganggntggn 120ggtggancct nantcgcagc agggtgtgtc cagatggtca gtctctggtg gctagcctgt 180cctgacaggg gagagttaag ctcccgctct ccaccgtgcc ggctgncaga gtgggctgag 240ggtgaccgag agaccagaac ctgcttgctg gagcttagtg ctcagagctg ggganggagg 300ttccgccgct cctctgntgt ca 322 61 155 DNA Homo sapiens Unsure 33 May be any nucleotide 61aaccctgtcc tggcttcccc tcccaaggag gantgaggat ggtgcctctg aggaaaacta 60tgtgcccgtc cagctcctcc agtccaactg atggcccaga tgcagcagga ggccagagga 120cagagcagag gatctttcca accacatctg ctggc 155 62 144 DNA Homo sapiens 62aattcactgg gaccccagag ccagcagatg tggttggaaa gatcctctgc tctgtcctct 60ggcctcctgc tgcatctggg ccatcagttg gactggagga gctggacggg cacatagttt 120tcctcagagg caccatcctc atcc 144 63 144 DNA Homo sapiens 63actgggaccc cagagccagc agatgtggtt ggaaagatcc tctgctctgt cctctggcct 60cctgctgcat ctgggccatc agttggactg gaggtgctgg acgggcacat agttttcctc 120agaggcacca tcctcatcct tctt 144 64 310 DNA Mus musculus 64gagaatggtt actggtggtg caggaggaaa aggcatcgcg cagggaggct gctgaaagtt 60ggcaccaaag gggatggtat acctgatgag cgctggtgct tcagggtgga ggaagtaaac 120tgggctgcat gggagaagac ccttcccacc ttatctgagg atccatcagg ggcaggcatc 180actggttata aaaagaaccc aacctctaaa cctgggaaga acagtgcctc agaggaagac 240catctgcctc ttcaggtcct ccagtcccac tgacggtcca gatgcggcac agcaggctgg 300cagggtagag 310 65 334 DNA Mus musculus 65ggaaaaggca tccgcaggga ggctgctgaa agttggcacc aaaggggatg gtatacctga 60tgagcgctgg tgcttcaggg tggaggaagt aaactgggct gcatgggaga agacccttcc 120caccttatct gaggatccat caggggcagg catcactggt tataaaaaga acccaacctc 180taaacctggg aagaacagtg cctcagagga agaccatctg cctcttcagg tcctccagtc 240ccactgacgg tccagatgcg gcacagcagg ctggcagggt agagtaggga attttgccag 300ccacacccga ggctactgaa ttttggtgga aata 334 66 447 DNA Mus musculus 66ttcggatcca tgcccgagag aacaccaacg tctgtcacca agatgtacga cctgctgctt 60ctcaagtgtt cacgcctctt ccccgccagc aacctggaga cagttctcaa caatgatggc 120ctttcgcctc tcatgatggc tgccaagaca ggcaagatcg gggtctttca gcacatcatc 180cgacgtgagg tgacagatga ggacacccgg catctgtctc gcaagttcaa ggactgggcc 240tatgggcctg tgtattcttc tctctacgac ctctcctccc tggacacatg cggggaggag 300gtgtccgtgc tggagatcct ggtgtacaac agcaagatcg agaaccgcca tgagatgctg 360gctgtagagc cattaacgaa ctgttgagag acaagtggcg taagtttggg gctgtgtcct 420tctacatcaa cgtggtctcc tatctgt 447 67 431 DNA Homo sapiens 67tcgcccctca gataagagtc aacctcaact accgaaagga acaggtgcca gtcagccgga 60tccaaaccga tttgaccgag atcggctctt caatgcggtc tcccggggtg tcccgaggat 120ctggctggac ttccagagta cctgagcaag accagcaagt acctcaccga ctcggaatac 180acagagggct ccacaggtaa gacgtgcctg atgaaggctg tgctgaacct taaggacggg 240gtcaatgcct gcattctgcc actgctgcag atcgaccggg actctggcaa tcctcagccc 300ctggtaaatg cccagtgcac agatgactat taccgaggcc acagcgctct gcacatcgcc 360attgagaaga ggagtctgca gtgtgtgaag ctcctggtgg agaatggggc caatgtgcat 420gcccgggcct g 431

Claims

1. An isolated polynucleotide comprising a nucleic acid selected from the group consisting of:(a) a nucleic acid encoding amino acids 1 to 889 of SEQ ID NO:2; (b) a nucleic acid encoding amino acids 2 to 889 of SEQ ID NO:2; and (c) a nucleic acid encoding the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203082; wherein said nucleic acid encodes a protein which mediates intracellular Ca+2 flux in response to thermal stimuli.

2. The isolated polynucleotide of claim 1, wherein said nucleic acid is (a).

3. The isolated polynucleotide of claim 1, wherein said nucleic acid is (b).

4. The isolated polynucleotide of claim 1, wherein said nucleic acid is (c).

5. The isolated polynucleotide of claim 1, further comprising a heterologous polynucleotide.

6. A method of producing a vector comprising inserting the isolated polynucleotide of claim 1, into a vector.

7. A vector comprising the isolated polynucleotide of claim 1.

8. The vector of claim 7, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

9. A host cell comprising the isolated polynucleotide of claim 1.

10. The host cell of claim 9, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

11. A method of producing a polypeptide comprising culturing the host cell of claim 10, under conditions such that a polypeptide is expressed, and recovering said polypeptide.

12. A composition comprising the isolated polynucleotide of claim 1 and a pharmaceutically acceptable carrier.

13. An isolated polynucleotide comprising a nucleic acid encoding a first amino acid sequence at least 95% identical to a reference amino acid sequence selected from the group consisting of:(a) amino acids 1 to 889 of SEQ ID NO:2; (b) amino acids 2 to 889 of SEQ ID NO:2; (c) the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203082; wherein said nucleic acid encodes a protein which mediates intracellular Ca+2 flux in response to thermal stimuli.

14. The isolated polynucleotide of claim 13, wherein said reference amino acid sequence is (a).

15. The isolated polynucleotide of claim 13, wherein said reference amino acid sequence is (b).

16. The isolated polynucleotide of claim 13, wherein said reference amino acid sequence is (c).

17. The isolated polynucleotide of claim 13, further comprising a heterologous polynucleotide.

18. A method of producing a vector comprising inserting the isolated polynucleotide of claim 13 into a vector.

19. A vector comprising the isolated polynucleotide of claim 13.

20. The vector of claim 19, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

21. A host cell comprising the isolated polynucleotide of claim 13.

22. The host cell of claim 21, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

23. A method of producing a polypeptide comprising culturing the host cell of claim 22 under conditions such that a polypeptide is expressed, and recovering said polypeptide.

24. A composition comprising the isolated polynucleotide of claim 13 and a pharmaceutically acceptable carrier.

25. An isolated polynucleotide comprising a first nucleic acid which hybridizes in a wash solution consisting of 0.1×SSC at 65° C., to a second nucleic acid selected from the group consisting of:(a) a nucleic acid consisting of the coding region of the cDNA clone contained in ATCC Deposit No. 203082 or the complement thereof; and (b) a nucleic acid consisting of the coding region of SEQ ID NO:1 or the complement thereof; wherein said first nucleic acid is 150 or more nucleotides long and said first nucleic acid does not comprise any one of SEQ ID NOs:18-67; and wherein said first nucleic acid encodes a protein which mediates intracellular Ca+2 flux in response to thermal stimuli.

26. The isolated polynucleotide of claim 25, further comprising a heterologous polynucleotide.

27. A method of producing a vector comprising inserting the isolated polynucleotide of claim 25 into a vector.

28. A vector comprising the isolated polynucleotide of claim 25.

29. The vector of claim 28, wherein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

30. A host cell comprising the isolated polynucleotide of claim 25.

31. The host cell of claim herein said isolated polynucleotide is operably associated with a heterologous regulatory sequence.

32. A method of producing a polypeptide comprising culturing the host cell of claim under conditions such that a polypeptide is expressed, and recovering said polypeptide.

33. A composition comprising the isolated polynucleotide of claim 25 and a pharmaceutically acceptable carrier.